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ABSTRACT 
Radiotherapy is one of the most widely used treatment modalities in modern 
oncology; it is constantly improving, with many high precision tools such as rectal 
spacers to decrease rectal wall toxicity being used to improve patient outcomes. This 
thesis explores the idea that in-vivo rectal wall measurements can be performed 
using Gafchromic EBT3 film deployed on a rectal spacer device known as 
Rectafix®.  
 
Two of the most complex and advanced radiotherapy prostate treatment modalities, 
Volumetric Modulated Arc Therapy (VMAT) and TomoTherapy® high precision 
prostate boost treatments were investigated by utilising a CIRS head and neck 
phantom with a modified Rectafix that allows  film to be housed during treatment.  
 
 An initial benchmarking study was carried out to test the response of film to a 
varying angle of incidence and depth of exposure. This method employed proved to 
be robust and the dose profile obtained from the Treatment Planning System (TPS) 
against the measured profile were a successful match according to report TRS-43071. 
 
High precision prostate boost plans for VMAT and TomoTherapy were created 
utilising existing patient data superimposed onto the CIRS head and neck phantom. 
The results were compared by extracting superior – inferior line profiles on the most 
anterior portion of the Rectafix® because it is the most at risk portion of the rectal 
wall to toxicity. 
 
A gamma analysis was performed with dose difference/Distance to Agreement 
(DTA) parameters set to 3%/3mm, 3/1%, 2%/1mm and 1%1mm with VMAT scoring 
100%, 98.7%, 98.2% and 89.2% with repeated measurements scoring 100%, 99.0%, 
98.2% and 86.0% respectively. The same dose difference/DTA parameters were 
utilised with TomoTherapy, scoring 100%, 98.5%, 97.3% and 85.0% and repeat 
TomoTherpy® measurement scoring 100%, 100%, 100% and 91.0% respectively. 
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The method investigated can provide enough information to verify whether treatment 
has been delivered to an acceptable level of accuracy. The dose objective set for the 
treatment plan was to limit the dose to the rectal wall to 14-16 Gy, but VMAT 
delivery delivered a much higher dose, 23.9 Gy to a portion of the rectal wall that 
risked unwanted toxicity. It was agreed that further investigation is needed before 
concluding the treatment; however the TomoTherpy® delivery was within the limits 
of the dose objectives so it was deemed safe to continue the treatment.   
 
The procedure outlined in this thesis shows this method detected deviations that 
could potentially deem the treatment to be unsafe to deliver. These may include 
small deviations in the setup, inter leaf leakage, or other unlikely variations in the 
parameter between the planned and delivered dose. With the help of the outlined 
procedure in this thesis, unwanted side effects can be predicted before they occur and 
avoided by replanning the treatment in order to increase positive outcomes for the 
patient.  
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1 Introduction 
 
 
1.1 A relatively new paradigm for fractionated prostate radiotherapy  
 
Based on the low alpha beta ratio1, hypo-fractionated prostate radiotherapy is now 
being examined in several new clinical trials2. A hybrid technique which involves 
standard fractionation with two large dose fractions as a boost is part of clinical trial 
in Australia.3 This trial enables either spacer Gel or Rectafix® to be used to optimise 
the space between rectal tissue and the prostate target.  
 
With such a high dose per fraction applied to the boost, delivering a precise dose to 
the rectal tissue is paramount. This thesis explores the hypothesis that it is better to 
ensure that the dose delivered to the rectal wall matches the dose calculated by the 
radiotherapy treatment planning computer, and thus avoid unexpected toxicity. This 
can be validated by the “end to end” pre- treatment QA dosimetry method devised 
and reported in this thesis. This proposed dosimetry method he uses EBT3 film 
wrapped onto a Rectafix® immobilisation spacer device. 
 
1.2 Thesis Aims 
 
This thesis addresses an investigation of the potential use of EBT3 film as an in-vivo 
dosimeter when attached to a rectal immobilisation and spacer device known as 
Rectafix®. All the experiments were pre-clinical and were carried out in a dosimetry 
phantom environment. The research questions we addressed in this investigation are 
as follows: 
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i. Can EBT3 film be positioned on Rectafix® device such that it simulates a 
dose at the rectal prostate interface? 
ii. Can EBT3film be calibrated and used at high dose per fraction doses 
(typically 8Gy)? 
iii. What is the accuracy and reproducibility of the   EBT3 film measurements? 
iv. How do the pre in-vivo EBT3 film measurements compare with radiotherapy 
treatment planning dose estimates for simple fields and for volumetric 
modulated arc (VMAT) dose delivery? 
v. How do the in phantom EBT3 film measurements compare with radiotherapy 
treatment planning dose calculations for TomoTherapy® delivery? 
 
1.3 Prostate Cancer 
 
The prostate consists of glandular, fibrous and muscular elements.  It is positioned 
inferiorly to the base of the bladder and houses the beginning of the urethra.  The vas 
deferens and seminal vesicle glands are attached to the posterosuperior section of the 
prostate. The prostate consists of four zones: the central, transition, fibromuscular, 
and the largest; the peripheral zone.12 
 
Prostate carcinomas most commonly i.e. ~75% occur in the peripheral zone, while 
benign prostatic hyperplasia (BPH) mostly occurs in the transition zone. Prostate 
cancer can extend to any of the other zones, as well as into the seminal vesicles, 
rectum and neck of the bladder. The likelihood of metastases to the lymph nodes and 
other regions of the body depends  on the size and degree of differentiation of the 
primary tumour.12 
 
Various methods are used to treat prostate cancer, and while there are a number of 
options there is no consensus on which is best. The optimal options which are best 
addressed by Urologists and or Oncologists and which the meet standard of care, 
vary somewhat depending on the grade/stage of tumour and patient performance and 
health status.19 
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The options available include active surveillance, radical prostatectomy, interstitial 
prostatic brachytherapy, external beam radiotherapy and cryotherapy.  It has been 
shown by level 1 data that radical prostectomy or radiotherapy confer longer overall 
survival and cancer specific survival compared with no treatment. 12 
 
There is no available data to prove the superiority of prostatectomy vs brachytherapy 
vs radiotherapy as there hasn’t been any randomized clinical trials which compared 
these treatments, prostate cancer progresses slowly and clinical selection is subject to 
selection bias.12  
 
In deciding for the most suited treatment for the patient the severity of the disease, 
life expectancy and patients’ base line performance. With low to intermediate risk 
patients who have a life expectancy of 10 years or less, treatment is not 
recommended. For patients with poor baseline performance when surgery is not 
recommended surveillance or radiotherapy may be the modality of choice. 12 
 
For young patients surgery may provide a better long term benefit.  Radical 
prostatectomy is widely used in order to treat prostate cancer of any risk level. For 
patients with intermediate to high risk, the prostate and seminal vesicles, as well as 
the pelvic lymph nodes are removed. This may be performed via open surgery 
approach or minimally invasive laparoscopic approach with or without robotic 
assistance, with equal oncologic outcomes. 12 
 
Interstitial brachytherapy, in which small seeds of iodine 125 or palladium 103 are 
inserted stereotacticly into the prostate under the guidance of ultrasonography, 
delivers a localized dose to the prostate while sparing nearby critical organs at risk. 
This may be performed using low dose rate brachytherapy were the seeds are left 
inside the prostate permanently or by using high dose rate brachytherapy in which 
seeds are inserted for a period of time and then removed. 12 
 
External beam radiotherapy, in which electrons, protons or neutrons are used to 
deliver radiation via an external source, although appear to have theoretical 
advantages, provide similar clinical efficiency. It has been proven effective in low, 
 
4 
intermediate and even high risk cancer when used in combination with androgen 
deprivation. It is non-invasive and effective at delivering a high dose to the target 
area with better uniformity in comparison to brachytherapy, but also delivers a higher 
dose of radiation to the surrounding critical structures. 12 
 
There is some evidence that an increased dose increases the local control of the 
tumour.20,21 Dose escalation in an external beam has mainly been at 2Gy per fraction, 
but dose escalation using an external beam with a brachytherapy boost has 
historically used a large dose per fraction. 18,20 
  
Hypofractionation is a beneficial method possibly because the prostate has a low α/β 
ratio, but due to the increased total treatment dose and dose per fraction, the need to 
verify an accurate delivery is an important factor.  
 
Historically, increased fractionation has been regarded as providing an increased 
therapeutic advantage because it spares late responding normal tissue more than 
tumours which respond like early responding tissue. This is still the paradigm for 
most tumours and clinical sites treated with radiotherapy. The α/β ratio in the linear 
quadratic (LQ) equation can be used as a measure to understand that fractionation 
spares late responding tissue, i.e. a low α/β ratio more than early responding tissue 
with a high α/β ratio. 1,12-14 
 
Prostate cancer may be the exception to the general rule due to having an α/β ratio 
for tumour that is similar to or even lower than the surrounding late responding 
normal tissue. 1,12-14 
 
Brenner and Hall stated that prostatic cancer appears to be much more sensitive to 
changes in fractionation than other cancers, and estimated the α/β ratio to be 
approximately 1.5 Gy. 1 There have been several other low values quoted for the α/β 
ratio; Brenner et al giving   =1.2 Gy14; Demanes et al. 1.2 Gy15; Martinez  et al. 
1.2 Gy; Lukka  et al 1.12;  Gy16 and Kupelian  et al. 1.1 Gy17 
Another view which contradicts this argument was proposed by Nahum et al.  where 
severe hypoxia in the prostate in certain cases is what limits the overall cure rate of 
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cancer treated using conventional radio therapy. Nahum states that the α/β ratio or 
the clonogen number must be extremely low to explain the response of prostate 
cancer to external beam therapy or brachytherapy. 18 Despite Nahum’s view, the 
consensus now as evidenced by several independent analyses of α/β is that the value 
for prostate cancer is very low.  
 
1.4 External Beam Radiotherapy 
 
External beam radiotherapy is one of the most common techniques used to treat 
cancer, with approximately 50% of all cancer patients receiving some form of 
radiotherapy as part of an optimal treatment.4 The aim is to administer a prescribed 
dose to the organ or area being treated, while minimising the dose received by the 
surrounding normal tissue. Obviously it is important to minimise acute and late side 
effects while preserving or increasing a patients’ quality of life. Radiation causes 
strand breaks by direct damage or indirect damage from free radical production. The 
effectiveness of radiotherapy is well recognised and has contributed significantly to 
improved cure rates and survival in recent decades. 5 
 
1.5 Radiobiological modelling and optimisation 
 
Radiobiology is a study of the effects of ionising radiation on human cells where 
radiobiological models are used to predict the effect of ionizing radiation on tumour 
cells and normal tissue cells. A number of models based on cell survival data are 
used to predict the very complex radiobiology mechanism effect that ionizing 
radiation has on tumours and normal tissue.  
 
The goal of radiotherapy is to eradicate tumour clonogens (tumour regenerating cell) 
by maximising damage to these cells while minimising damage to normal tissue cells 
in order to maximise the benefit and minimise any unwanted side effects. As local 
tumour control increases, the side effects that follow must also be reduced because 
patients are surviving for longer periods of time post radiotherapy. 6 Predictions from 
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radiobiological odels combined with the outcomes of clinical trials are used by 
clinicians to tailor dose distributions according to tumour control and normal tissue 
toxicity. Radiobiology theories and the response of cells to ionization radiation are 
constantly changing and being updated.  In the discussion following in this thesis the 
linear quadratic radiobiological model is covered for tumour control and the Lyman 
Kutcher-Burman model for normal tissue toxicity. While the models are not an 
integral part of the dosimetry experiment, they do help to explain how 
radiobiological modelling is shaping prostate clinical trials.  
 
1.5.1 The mechanism of cell killing 
 
Radiotherapy is based on the principle of killing tumour clonogens whilst minimising 
the damage done to surrounding normal tissue. Ionization radiation deposits energy 
into DNA strands and causes damage to the cells via either direct or indirect cell 
death. Direct cell deaths occur when electrons cause a double strand break (DSB) 
and single strand break (SSB) in the DNA. Although there are mechanisms in which 
cells can repair, not all the DSB are repaired or not, leading to cell death. Indirect cell 
death occurs as a result of free radicals, the most dominant one being the –OH 
molecule, produced by the ionization of water molecules.  
 
The linear quadratic model can be used to increase our understanding of how 
changes in the parameters can affect cell survivability. The liner quadratic (LQ) 
model states that:7 
  
𝑠 = 𝑒𝑥𝑝(−𝑛𝑑 (∝ +𝛽𝑑)) (1.1) 
 
Where S is the surviving fraction of cells and d is the radiation dose in Gyp per 
fraction, n is the number of fractions, and α and β are the radiosensitive parameters 
which dictate the sensitivity to change between different types of tissue.  This 
difference in sensitivity between tumour and normal cells dictates the fractionation 
regimen, because the α/β ratio is a recognised historical method of determining the 
sensitivity to change in different tissues.  
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1.6 Hypofractionation 
 
There has been interest in the fraction size used in the treatment of prostate cancer.  
Standard radiotherapy treatment fraction size in 2 Gy per fraction. Hypofractionated 
radiotherapy is when a dose higher than 2 Gy per fraction is delivered reducing the 
time of the treatment. The α/β ratio in the linear quadratic equation can be used as a 
measure to understand that fractionation spares late responding tissue, i.e. a low α/β 
ratio has more than with early responding tissue compared with a high α/β ratio. The 
α/β ratio is the dose in which the linear component and the quadratic component of 
the linear quadratic equation cause equal amount of cell death. Thus better tumour 
control can be achieved with a higher dose per fraction, with similar side effects. 1,12-
14 
 
Prostate cancer may be the exception to the general rule because it is thought to have 
an α/β ratio for tumour that is similar or even lower than the surrounding late 
responding normal tissue. 1,12-14 
 
Brenner and Hall stated that prostatic cancer appears to be much more sensitive to 
changes in fractionation than other cancers, and estimated the α/β ratio to be 
approximately 1.5 Gy. 1 There have been several other low values quoted for the α/β 
ratio; Brenner et al giving   =1.2 Gy14; Demanes et al. 1.2 Gy15; Martinez  et al. 
1.2 Gy; Lukka  et al 1.12;  Gy16 and Kupelian  et al. 1.1 Gy17. 
 
This low α/β for prostate implies that the prostate BED may always be greater than 
late responding normal tissue, which is why hypofractionation is of benefit in 
radiotherapy for prostate cancer because it delivers a higher than standard 
(2Gy/fraction) dose in fewer fractions. This fractionation regime has 2 advantages 
compared to a standard fractionation regime; first it allows for a reduction in late 
rectal BED for an equivalent prostate BED compared to a standard fractionation 
regime, and it provides a greater prostate BED for an equivalent prostate BED 
compared to a standard fractionation regime. 
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Another view which contradicts this argument was proposed by Nahum et al. who 
argued that severe hypoxia in the prostate in certain cases is what limits the overall 
cure rate for cancer treated by conventional radio therapy. Nahum states that the α/β 
ratio or the clonogen number must be very low in order to explain the response of 
prostate cancer to external beam therapy or brachytherapy. 18 Despite the view of 
Nahum, the consensus view now, as evidenced by several independent analyses of 
α/β, is that the value for prostate cancer is very low.  
 
1.7 Volumetric modulated Arc Radiotherapy (VMAT) 
 
Many technological advances have been made in the delivery of external beam 
radiotherapy. The use of multi leaf collimators (MLCs) to create conformal and 
modulated dose distributions has helped to reduce the dose to normal surrounding 
tissue, although there is still some dose to normal tissue due to combinations of 
scattered and leaked radiation. This low dose may still induce a probability of late 
effects or short term toxicity, induced secondary malignancies, all of which  
emphasises the need for a careful characterisation of planned dose to the patient. 30 
 
Volumetric modulated arc therapy (VMAT) is a technique for delivering intensity 
modulated radiotherapy (IMRT) in a continuous manner while the linac rotates in an 
arc around the patient. 31 The dynamic aperture shaping of a multi lead collimator 
(MLC) of a conventional linear accelerator makes VMAT possible. Like IMRT, 
VMAT can produce intensity modulated dose distributions and deliver them in a 
much shorter time frame. 32 Unlike IMRT, VMAT makes use of all the gantry angles, 
but without any instantaneous beam intensities.  
 
To produce plans with much shorter treatment times than IMRT, VMAT delivery 
utilises MLC segments spaced equidistantly apart and then inversely optimised; the 
level of modulation dictates the gantry spacing required. This treatment planning 
system approximates the continuous dose delivery through a coarse representation of 
an arc, e.g. every 4 degrees, and means that the patient dose will be under-sampled at 
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distances further away from the rotational axis (i.e. the isocentre). Treatment 
planning software allows this parameter to be adjusted. 33 
VMAT planning demands that a linear accelerator is able to deliver a number of 
different MLC shapes in an arc, with each of them having a number of different 
monitor units. However, due to physical restraints of the linac the dose rate and/or 
the gantry speed must be modulated between each control point. 31 The MLC speed 
is what ultimately determines the dose rate and the gantry speed.  Modern control 
systems can now vary these parameters individually, 34 this means the gantry speed, 
dose rate, and individual MLC speed are all controlled individually to achieve a 
highly conformal dose delivery. 
 
1.8 TomoTherapy® 
 
TomoTherapy® is another method for delivering EBRT.  Helical TomoTherapy® is 
a technology that allows IMRT to be delivered with 3D image guidance capability, 
while providing modulated dose maps during a linac arc, just like VMAT. However, 
the delivery method is significantly different to VMAT because it uses a 6 MV linear 
accelerator which rotates while producing binary modulated fan beams on a slip ring 
CT gantry to deliver a dose helically. 35 
 
The fan beam is produced by a 64 leaf binary MLC set up where the fan beams are 
modulated as a function of the gantry angle. A very high level of intensity 
modulation can be achieved by using a large number of beam angles per gantry 
rotation, along with the MLC open-close time being small (20 ms to open or close), 
pneumatically operated MLCs moving at 100 times the speed of a conventional linac 
makes this possible.36  
 
Binary MLCs produce a 1D profile that is continually modified, and when combined 
with the continuous rotation of the beam, produces a 2D profile. The couch moves 
through the bore of the gantry, which allows the dose to be painted helically around 
the patient and minimise any potential overdosing or underdoing at any point. 37 38 
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This system can acquire MVCT images via the on board CT detectors; this helps to 
verify the pre-treatment setup, dose reconstruction, delivery verification, and carry 
out regular quality control procedures.  39 40  
The pitch, modulation factor, and widths of the collimator are planning parameters 
that may be adjusted during the treatment planning phase to achieve the desired dose 
modulation, treatment time, and resolution. The distance the couch travels in the time 
it takes for a complete gantry rotation with respect to the width of the beam on the 
axis of rotation is defined as the pitch. The trade-off between the freedom and 
optimisation of the plan to allow for variations of beam intensities to achieve its 
goals is called the modulation factor (MF). 35 
 
The pitch chosen can introduce an unwanted dosimetric artefact known as  the helical 
tomotherapy thread effect41 where beam junctioning appears to create dose ripples 
artefacts. This is a unique effect for tomotherapy and it is minimised by making use 
of  a pitch value equal to p=0.86/n (n is an integer).41 
 
With the advancements in radiation therapy techniques high precision treatment 
techniques such as VMAT and TomoTherapy have proven to be better at better 
coverage of the PTV also while sparing the OAR more than conventional IMRT. 
Although there have been planning studies comparing these two modalities, there is 
no agreement as to which technique is superior. Although it is observed that VMAT 
provides a faster treatment time.86  
 
S. Awakada et. al have performed a study in which they have performed a 
comparison study using the same dose-volume parameters of VMAT and HT for 
prostate cancer by using the identical dose prescription to 95% of the PTV. Identical 
treatment plans were created for 15 patients and prescription dose delivered was 74.8 
Gy in 34 fractions for 95% of the PTV to receive 90% of the prescription dose in 
both plans. It was observed that there were a number of significant differences in a 
number of volume parameters but they were not so large. While TomoTherapy plans 
provided a more homogenous dose distribution in PTV and lower rectum doses, 
while the VMAT plans were observed to have more conformable plans, lower 
bladder doses and shorted delivery time. 87 
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1.9 Rectal Toxicity 
 
Limiting the dose and the volume of rectal wall irradiated is an important factor in 
minimising acute rectal effects post radiotherapy. These effects may become 
apparent during or soon after radiotherapy and include softer or diarrhoea like stools, 
and rectal tightness along with cramping and frequent pain. In some cases superficial 
ulceration may cause bleeding that may require endoscopic cauterisation known as 
radiation induced proctitis. Other complications may also arise 3 to 4 years post 
treatment that are classified as late effects, and may include stricture, decreased 
rectal compliance, and decreased storage capacity which causes small and frequent 
bowl movements. In more severe cases where injury has occurred to the anal 
musculature, other problems may arise such as fecal incontinence or stricture; these 
injuries can be severe and have a negative effect on patient’s quality of life.  
 
During CT scans and subsequent treatment, the rectum is more likely not to be in the 
same position due to movement caused by interfraction and intrafraction variations in 
rectal filling, and intestinal gas and bladder filling. This creates uncertainty during 
treatment.  
 
The most frequently quoted endpoint used in published data make use of either rectal 
bleeding or the Radiation Therapy Oncology Group (RTGO) Grade rectal toxicity 
scoring system21. The RTGO scale considers Grade 2 toxicity to include moderate 
diarrhoea and colic, more than 5 bowel movements per day, excessive rectal mucus, 
or some bleeding. Grade 3 toxicity includes obstruction or bleeding which requires 
surgery; but Grade 4 necrosis/perforation fistula is rarely encountered in the current 
radiation therapy modalities. A summary of the incidence of toxicity endpoints can 
be found in Table 1-1.  
At lower doses a large amount of rectal volume must be subjected to intermediate 
doses before substantial toxicity is seen. The convergence of dose-volume data at 
>70Gy and <20% volume obtained from multiple centres implies that toxicity is 
mostly associated with the high dose range22. 
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For a conservative treatment plan the dose-volume constraints should be used as a 
starting point: V50 < 50%, V60 < 35%, V65 < 25%, V70 < 20%, and V75 < 15%. The 
NTCP models predict that following this guideline should limit Grade ≥2 late rectal 
toxicity to <15% and the probability of Grade ≥3 late rectal toxicity to <10% for 
prescriptions up to 79.2 Gy in standard 1.8- to 2-Gy fractions. 
 
 
Authors 
(reference) 
Endpoint  Total prescribed 
dose (Gy)/f  
Incid
ence 
(%) 
Tucker et 
al.23 
Grade ≥2 RTOG 68.4, 
73.2,79.2/1.874, 
78/2 
13.5 
Söhn et 
al.24 
Grade ≥2 Common Terminology Criteria 
for Adverse Events (CTCAE) v3.0 
70.2, 
72,73.8,75.6, 
77.4, 79.2/1.8 
16 
Rancati et 
al.25 
Grade ≥2 bleeding 64–79.2/1.8–2 7 
  70–79.2/1.8–2 6.9 
 Grade ≥3 bleeding 64–79.2/1.8–2 1.6 
Peeters et 
al.26 
Bleeding 68 (n = 234),78 (n 
= 234)/2 
4.9 
 Frequency  6.4 
 Fecal incontinence  6.8 
Cheung et 
al.27 
Grade ≥2 toxicity, modified scale 78/2 22.7 
 Without haemorrhoids 16.7 (14/ 84)  16.7 
Burman et 
al.28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
Severe proctitis, necrosis, fistula, and 
stenosis
  
Table 1-1 Description of endpoints, Lyman-Kutcher-Burman NTCP model 
parameters for published analyses 22 
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Patients treated with IMRT are reported to have lower rates of complication than 
those treated with standard 3D-CRT29. 
 
1.10 Rectafix® 
 
The distance between the prostate (target) and the rectum (organ at risk) is close, 
which leads to a compromise between dose to target and organ at risk.42 
 
The Rectafix® is a device designed to reduce the dose received by the rectal wall to 
reduce side effects from rectal wall irradiation. A Rectafix® is a rod inserted into the 
rectum, angled in the posterior direction, and secured by a vertical column. . Once 
the Rectafix® is inside the rectum, it is then moved posteriorly to move the rectum 
away from the prostate by 20-25 mm. Rectafix® has found a niche in proton therapy 
boosts and photon boosts to treat prostate cancer. 42,43,44 
 
A study carried out by Sarah Alnaghy et.al. placed MOSkin™ detectors onto a 
surrogate Perspex Rectafix® device to obtain real time dose measurements along the 
rectal wall. They used single detectors to measure the dose at the rectal wall with 
±5% of the TPS on 87.5% of the detectors. They then used a dual MOSkin™ system 
to obtain acceptable agreement with all the detectors.45 A graph of measured 
absorbed dose to TPS on the anterior edge of the solid Perspex probe can be found in 
Figure 1-1.  
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Figure 1-1 Graph of absorbed dose, TPS in comparison to dose measured 
experimentally using four MOSkin™ detectors on a solid Perspex probe. Graph 
taken from Sarah Alnaghy et. al. 2014 45  
  
The benefit of running MOSkin™ detectors is that they are real time dosimeters and 
can feed dose data online while treatment is taking place; this means that errors can 
be detected during treatment and intervention can occur before the patient has 
received an incorrect dose. The study carried out in this thesis was able to obtain the 
dose received by a large portion of the rectal wall with high resolution, giving it the 
ability to detect high variations of dose over a small distance. A 2-D dose map can be 
created of the dose received by the rectal wall; this is much better than the high dose 
gradient setting in which this experiment was conducted.  
 
A study performed by Isacsson et al (2010) compared treatment plans with and 
without rectal wall retraction in the same 9 patients. All the patients in this study 
were biopsy proven with localised adenocarcinoma of the prostate. A cylindrical 
Perspex rod of 1.5 cm in diameter was inserted into the rectum and then retracted 
posteriorly. 3 radiopaque markers were used for position verification using both the 
planning CT scans and x-rays.  The patients were given a proton boost of 20 Gy in 
four fractions of 5 Gy, as well as a dose of 50 Gy in 25 fractions of 2 Gy using 
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conventional photon beam treatment.  Comparative treatment planning showed that 
the volume of rectal wall retraction significantly reduced the volume of wall 
receiving high doses, in all patients. The volume that received 70 Gy in 2 fractions 
during the boost was reduced by 5-96% (average of 67%). The average dose 
reduction received by the rectum was 5. An average difference of 0.4 mm was found 
between the retractor markers on the planning CT and the images taken during 
treatment. 42 
 
Nilsson et al compared two different treatment plans for 10 different patients being 
treated for prostate adenocarcinoma. Treatment plans were produced using VMAT 
for ten patients with and without rectal retraction, and a hypofractionation scheme of 
42.7 Gy in seven fractions was used. Four dose volumetric criteria were used to 
evaluate the rectal wall dose: V40.1 Gy, V38.3 Gy, V36.5 Gy, and V32.6 Gy. This recreation of 
the rectal wall increased the distance between the rectal wall and the prostate. 
Moreover, the rectal wall volume decreased to zero for all dose measurements except 
V32.6 Gy, which was 0.2 cm
3 on average when the rectal retractor was used. This 
operation was carried out without compromising the dose coverage of the panning 
target volume (PTV).  43 
 
1.11 Fiducial Marker 
 
Fiducial markers are used in a wide range of medical imaging applications. Modern 
radiation therapy techniques such as computed tomography (CT), Magnetic 
resonance imaging (MRI) and position emission tomography (PET) accurately define 
the target and deliver radiation in a safe manner to better localise a tumour. 51 
 
Tumour and normal tissue motion intra-fraction and inter-fraction poses a major 
challenge to the delivery of highly conformal radiation therapy techniques.  Since a 
prostate is a highly mobile target due to errors arising from setting patients up, 
because there are no nearby structures visible to kVCT or MVCT imaging pre-
treatment, and also due to bladder volume, rectal distension, levator contractions, and 
even respiration.52 
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Fiducial markers are a very useful tool to assist with registration, tracking inter-
fraction and intra-fraction motion, and measuring any difference between the 
position, from the process of simulation to treatment planning to treatment 
guidance.53 
 
 Fiducial markers are commonly placed within the target volume or adjacent to it 
prior to radiotherapy simulation as a surrogate for the target volume because tumours 
are often difficult to visualise using the 2D IGRT modalities presently available. 
Fiducial markers should be easy to identify and be visible in simulation and 
treatment verification images. This aids in pre-treatment verification of the target 
position in order to treat the target precisely while also helping to spare the 
surrounding normal tissue.53 This is vital in prostate cancer because the rectal wall is 
sensitive to radiation, and when irradiated it can cause complications for the patient.  
 
 Daily localisation has become routine in many radiotherapy clinics thanks to the 
linac based on-board kVCT and the time saving MVCT orthogonal fiducial imaging, 
unlike conventional  CBCT.53 Fiducials can also be used with CBCT where soft 
tissue contrast is low.  
 
As MRI emerges into a useful modality for treatment planning54, having fiducial 
markers that are visible to the MRI and CT imaging modalities is vital, during 
treatment and simulation. 53 
 
 PolyMark (CIVCO Medical Solution, Orange City, IA) fiducial markers were used 
here because they are visible in CT, CBCT and MRI, but have poor visibility in 
EPID-MV.  Chan et. al. noted that attention should be given to the CT protocol and 
the MR sequences in order to reduce image artefacts and unclear visibility of the 
markers.53  
 
PolyMark™ (CIVCO Medical Solution, Orange City, IA) is the first polymer based 
biocompatible marker. It contains a stainless steel core with a PEEK-optima shell. It 
has dimensions of 1 x 3 mm, its density is 1.32 g/cm3, relative electron density if 
 
17 
1.24 and a relative opaque thickness of 1 during kV imaging. It minimizes artifacts 
and is visible during kV based IGRT, MRI and is optimized for proton therapy. 51, 53   
A study carried out by Alnaghy et al. used MOSkin™ detectors on top of a probe 
during a TomoTherapy® boost SRS treatment.45 The rotational positioning of the 
probe was an issue because while the MV scans performed pre measurements, the 
MOSkin™ detectors were invisible because they were too small to be seen in this 
imaging modality. In the KV images taken pre measurements, the MOSkin™  
detectors were difficult to image because the kV energy x-rays experience beam 
hardening, scatter and Poisson noise when exposed to high Z materials that lead to 
streak artefacts.55 
   
To overcome the rotational positioning problem that occurred in this study, 
polymark® fiducials were inserted into the Rectafix®. These fiducials are optimised 
for MR and are visible in CT; so they were used as a parallel study on the visibility 
of fiducials utilising MRI scans. This increased geometric accuracy of the Rectafix® 
device one of many imaging techniques in use, i.e. CT, VMAT and tomotherapy 
scans.   
 
1.12 In vivo dosimetry 
 
In-vivo dosimetry is a method of monitoring the actual dose delivered to a patient 
instead of relying on the planned dose being accurate; it can be used as a safety 
measure in treatment delivery. A dosimeter is placed inside or on the top surface of 
the patient being treated, wherever the dose must be measured. It has been stated in 
the ICRU report 24 (1976) that the best way to check the actual dose received by a 
patient is by performing in-vivo dosimetry.  
 
In-vivo dosimetry is therefore an appealing method to verify the dose received by the 
rectal wall, so in-vivo dosimetry of the anterior section of the rectal wall would 
enable the dose received by the section that usually receives the highest dose to be 
measured. Due to the high doses delivered during hypofractionation schedules to the 
prostate and anterior rectal wall, this dose must be calculated to correlate the rectal 
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toxicities to the delivered dose. In-vivo dosimetry would also help to verify the 
calculated target dose, and since the anterior rectal wall is included inside the PTV, a 
dosimeter placed inside the rectal wall would be a surrogate for the PTV dose at the 
posterior end of the volume. There has been a focus on implantable in-vivo 
dosimeters to verify target doses, as reported by Beyer et al 200746, Black et al 
200547, Kry el al 200948, Fagerstrom et al 200849, Scarantino et al 2005, 200850 49. 
These methods can be used for prostate radiotherapy, while  the implanted dosimeter 
can be used for position verification and to move the rectal wall away from the 
prostate to reduce its volume and the dose received by the prostate48.  
 
1.13 Properties of EBT3 film and suggestions for use 
 
Gafchromic EBT3 film is a type of commercial radiation-induced auto-developing 
photon and electron-beam analysis film that is available for therapeutic radiation 
dosimetry in radiotherapy applications to provide accurate in-vivo dosimetry 
measurements56. This film uses the principle of a polymer changing colour when 
irradiated; film that displays this property is generically referred to as radiochromic 
film. 
 
In this study we used Gafchromic EBT3 (lot number 12171302, Ashland speciality 
Ingredients, NJ, USA) radiochromic film because it allowed f large field areas to be 
detected with an adequate dose response in terms of energy dependence and linearity. 
It has a high dose range and a high spatial resolution that is restricted mainly by the 
resolution of the densitometer. Moreover, its high dose capability allows it to be used 
to study high dose gradients in the penumbra, it also has a linear dose response over a 
large range of dose, and it is also tissue equivalent which makes it ideal for an in 
vivo study.56, 67, 82, 83, 84, 85 
 
Gafchromic EBT3 radiochromic dosimetry film consists of a single active layer, 
nominally 27 μm thick, that contains an active component, marker dye, stabilisers 
and other additives that give the film its low-energy dependence. The yellow marker 
dye decreases UV/light sensitivity, and when used in conjunction with an RGB film 
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scanner permits the use of multi-channel dosimetry. The active layer is between two, 
120 μm transparent polyester substrates; this symmetric arrangement ensures 
consistent response regardless of which side of the film is facing the light source of 
the scanner. This composition can be visualised in Figure 1-2.  The polyester 
substrate has a unique surface treatment with microscopic silica particles that 
maintain a gap between the surface of the film and the glass window in a flatbed 
scanner. Since the gap is almost ten times the wavelength of visible light, it prevents 
the formation of Newton’s Rings interference patterns in images obtained using the 
flatbed scanners.57 
 
 
Figure 1-2 Gafchromic EBT3 film composition 
 
Gafchromic EBT3 film is self-developing, which reduces the possibility of error due 
to variations in chemical processing analysis, as long as a strict protocol such as time 
to read out is followed; it is not very sensitive to visible light, it is not brittle and can 
be bent and shaped to a certain degree, and it does spring back into its original shape 
as long as a crease is not induced while bending.  
 
There are also some challenges that arise using  EBT3 film which should be 
considered; for example, its sensitivity varies with temperature and UV light; its self-
development takes a couple of days; it’s  response is non-linear at low doses, and 
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there are possible variations in zero dose EBT3film response caused by interbatch 
and intrabatch variations. 58, 67, 84 Adhering to a fixed and consistent protocol is 
crucial in EBT3  film dosimetry to gain reproducible results.59 
 
When Gafchromic EBT3 film is exposed to ionizing radiation, colouration due to an 
attenuation of some of the visible light coming through the developed EBT3 film 
occurs, which darkens its appearance. This reduction in light passing through the 
EBT3 film is a measure of its “blackness” or “optical density” (OD). It is assumed 
that the dose to the EBT3 film is shown by the resulting optical density. The 
relationship for optical density is: 
 
𝑁𝑒𝑡 𝑂𝐷 = 𝑙𝑜𝑔10[
𝐼𝑜
𝐼
]       Equation 1-2 
  
Where 𝐼𝑜 is the light intensity with EBT3 film given no dose and I is the light 
intensity after EBT3 film is exposed to a dose of radiation.60, 67, 83, 84 
 
To calibrate the EBT3 film, it is irradiated by a known calibrated linac dose at a 
known distance from the source to the EBT3 film. When the change in colour is 
analysed there is an OD which represents the dose absorbed in the particular 
irradiation; this is then repeated with different times, calibrated dose or distances, 
and from which a trend is determined. 
 
Since Gafchromic EBT3 film batches have a linear response to an increasing dose 
(after ~50 cGy)61, a calibration factor emerges that will allow the dose incident on 
any EBT3 film of the same batch to be determined.  
  
The response of radiochromic dosimeters can be influenced by the temperature and 
relative humidity, and in some cases by ambient light and gases, and since the 
conditions between calibration and practical use may differ, variations of response 
with the surrounding conditions must be determined and corrected.62, 67, 84 
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Gafchromic EBT3 film is designed to be handled in interior room light, so it is 
recommended that the EBT3 film be kept in the dark when not in use and exposure 
to sunlight be avoided.60, 67, 84 
 
These EBT3 films are placed inside an envelope when not in use to avoid the effect 
of ambient light and other light sources during storage. It is important to minimise 
their exposure to light so any ambient light should be approximately equal for all  
EBT3 film; therefore all EBT3 film batches should be housed together  to maintain 
their consistency. This also ensures the same thermal background for all the EBT3 
film because EBT3 film is sensitive to temperature.60, 67, 84  
 
EBT3 film may be stored at room temperature (20˚ - 25˚C) but is best stored at 
refrigerator temperature, or less. Brief exposures (e.g. < 1min.) at temperatures of 
50˚C should not affect EBT3 film, but sustained exposure of unexposed EBT3 film 
to temperatures >60 °C may cause a significant change in sensitivity. 62 
 
Gloves should be used while handling EBT3 film to keep it clean and free of oil. 
Cotton gloves seem to be appropriate. Care should be taken not to stain or scratch the 
EBT3 film because it will affect the colour and in turn, the results.63 Prior to use, 
EBT3 films should be visually inspected and handled with care. The EBT3 film will 
turn from clear to a milky white at a damaged location, while the cut edges may be 
stressed and should be avoided for dosimetry analysis. It is recommended that the 
light beam of the scanner be kept about 1.5 mm away from a cut edge. 62, 67, 84 
 
Gafchromic EBT3 film is easy to work with and shape, it is not brittle so it can be 
bent and shaped according to what it will be used to measure. 62   
 
The lot number and model number of the EBT3 film should be recorded for each and 
subsequent experiments; this will enable the user to verify any manufacturing 
variations in the EBT3 film. 62 
 
The orientation and alignment of the EBT3 film should be noted, and since  EBT3 is 
non- polarised it is not angular dependent like its predecessor EBT2 film, however it 
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is important to record film orientation during irradiation and scanning to have a 
record of orientation. One method is to consistently mark and number the same 
corner of the film; this also keeps track of where the film was used. 62 
 
The film should be placed inside a phantom that is appropriate for the experiment 
being undertaken. For calibration purposes,  EBT3 film should be placed between 
layers of solid water and perpendicular to the linac beam, with at least 10cm 
underlying backscatter material.64 The orientation of the film should be noted and 
laser alignment points marked for analysis at a future time. 64 
Almost full colour development of all radiochromic formulations is very rapid, 
generally occurring in a few milliseconds, but several chemical effects in plastic 
systems induced by radiation require some time to reach chemical completion after 
irradiation. 62, 65, 67, 83, 84 
 
Keeping within the same time period between irradiation and scanning of films is 
crucial in obtaining measurements to minimise potential uncertainties due to dose 
dependent post irradiation darkening.62,65, 67, 82 
 
Although the main part of colour development occurs immediately during exposure, 
radiochromic films exhibit a strong dose dependent darkening of up to 20% OD 
during the first couple of hours after irradiation.59 
 
Moreover, a 22 hour period of irradiation to scanning time induced OD changes 
below 0.45% per hour for EBT3 film. Therefore, uncertainties of 2h-time delays 
remain within the tolerable uncertainty limits (<2%) and a 20h to 24h time window 
between irradiation and scanning can be assumed as being accurate enough. 59, 67, 82 
 
A 48 hour irradiation to scan time is ideal,  64  so a 42 to 50 hour window was used in 
this study scan the films post irradiation because it offered practical benefits for the 
user and it maximised the potential post irradiation colour development. 
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2 Materials and Protocols 
 
2.1 Linac  
 
An Elekta Synergy linear accelerator (Elekta Oncology Systems, Crawley, UK) was 
used to calibrate the film and deliver the VMAT plan.   The TomoTherapy® machine 
was a TomoTherapy® HI-ART II superposition-convolution system; both machines 
are located at the Liverpool Cancer Therapy Centre in Western Sydney.  
 
2.2 Treatment Planning System (TPS)  
 
Computerised treatment planning systems (TPS) were used to calculate dose maps on 
CT data sets prior to patient treatment and the CT data sets were obtained using a 2 
mm slice thickness on the Siemens Sensation 4 Multislice CT scanner (Siemens 
Medical Solutions, Malvern, PA); these calculations can also be performed on 
phantoms by using CT data sets. One main objective of this study was to compare 
the dose delivered on the Rectafix® with the dose predicted by the treatment 
planning system. 
 
The TPS used to calculate the dose from the linear accelerator VMAT deliveries was 
a Pinnacle treatment planning system (Philips Radiation Oncology Systems, 
Fitchburg, WI Version 9.0). Pinnacle incorporates the collapsed cone dose method of 
calculation .66 A 1.00 x 1.00 1.00 mm3 dose grid was used to calculate all the doses 
via a collapsed cone convolution. 
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The TomoTherapy® planning station version 4.2 (Accuray Incorporated) TPS was 
utilised to calculate all the doses  for the TomoTherapy® system before dose 
delivery; this consisted of a  2.00 x 2.00 2.00 mm3 dose grid for dose calculations 
using a convolution superposition method.66 
 
2.3 Phantom 
 
A Solid Water phantom (Gammex RMI, Middleton, WI) with the uniformity, water 
equivalence, and ability to vary thickness was utilised to carry out calibration and 
simple field tests.  
 
An IMRT Head and Torso Freepoint Phantom (CIRS, model 002H9K) was used for 
Rectafix® measurements. This phantom is constructed from tissue equivalent, epoxy 
materials with cylindrical cavities that allow rods to be inserted. These rods that can 
hold an ionization chamber or they can be made from bone equivalent material. The 
cylindrical cavities could also be rotated and placed in different positions. It is these 
cavities into which the Rectafix® was inserted. 45 
 
2.4 Rectafix® sleeve 
 
The diameter of the insertion point on the CIRS phantom was wider and longer than 
the Rectafix® device, so a sleeve was made from polyoxymethylene to obtain a 
secure fit between the Rectafix® and the phantom. . Polyoxymethylene was used 
because the Rectafix® is constructed from polyoxymethylene.  The sleeve also 
houses the film and secures it in place around the Rectafix® device.  
 
 Polyoxymethylene (CH2O)n is an engineering resin with mechanical properties that 
make it suitable to be used prototyping and manufacture of laboratory apparatus. The 
characteristics of Polyoxymethylene include metal-like machining and dimensional 
stability, as well as thermal stability.88 
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The Rectafix® is 20 mm in diameter, the insertion point on the CIRS phantom is 25 
mm in diameter, and the film is ~1mm thick. The sleeve has an outside diameter of 
25 mm and an inside diameter of 21 mm; it is  120 mm long so that it fills the gap in 
the length of the insertion point on the CIRS phantom. This ensures that the insertion 
point is filled with polyoxymethylene, it has no air gap, and the Rectafix® and film 
is securely in place.   
 
 
Figure 2-1 Image of the Rectafix® sleeve. 
 
The inside diameter of the sleeve was machined and polished to avoid damaging the 
film whilst inserting and removing it from the sleeve.  
 
2.5 Fiducials 
 
Fiducial markers are placed inside the Rectafix® device to verify its position inside 
the phantom by using the on board imaging modalities offered by the Elekta Synergy 
linear accelerator and TomoTherapy® HI-ART II machines.  
 
Since the Rectafix® is cylindrical and measurements are taken in a high dose 
gradient, even a small rotational error in the set up could produce a large readout 
error on the film.  
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Figure 2-2  Rectafix® device with 3 fiducials implanted. 
 
Three Polymark fiducial markers were placed onto the Rectafix®; two were placed 5 
cm apart on the superior edge of the Rectafix® and one marker was placed between 
the other 2 fiducial markers at 900. . This orientation allowed for the Rectafix® to be 
corrected in the sagittal, coronal and axial planes, as well as corrections for any 
rotation that may occur in a phantom set up.  
 
By using imaging data obtained pre-treatment, the fiducial markers were used as a 
reference point for the detector and to verify the position of the Rectafix® before 
commencing treatment.  
 
2.6 Film Cutting 
 
Since there is only a set of guidelines and no protocol recommended for dosimetry 
with EBT3 film, being consistent with each individual method in order to have data 
that can be inter-compared and be consistently reproduced over multiple experiments 
is very important. This report uses methods that are a conjugate of several suggested 
protocols, including A. Niroomand-Rad et. al. (1998) 62, N. Farah et. al. (2014) 63, S. 
Devic et. al. (2005) 64, C. Huet et. al. (2014) 65, P. Papaconstadopoulos et. al. (2014) 
67, N. Bennie and P. Metcalfe 68. 
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 At least one publication suggests cutting film with scissors because the equal 
pressure from the scissors helps keep the sandwich type layers from separating. 64 
With film, scissors should be used although good results can also be obtained by 
using a scalpel, a guillotine cutter, or a sharp knife.  
 
The cut edge of the film may be stressed and cause OD abnormalities which should 
be avoided for dosimetry analysis. It is also recommended that the light analysis 
beam be kept about 1.5 mm away from the cut edge. 62 
 
Since the outer layers of EBT3 films are polyester they can be marked with a felt tip 
permanent marker or pen without damaging the active layer. If the marks interfere 
with scanning or other measurements, they can be removed with a soft rag or tissue 
moistened with a solvent which does not damage the polyester.62 These marks may 
also be removed using image analysis software. 
 
The lot number and model number of the film was noted for each box of film; this 
helps the user trace any manufacturing variations to a particular batch of film. 62 
 
2.7 Flatbed scanner 
 
Although not specifically intended for radiochromic film dosimetry, document 
scanners can be used for measurements in various film dosimetry applications. 
Flatbed document scanners intended for high quality photographic scanning that 
prefer to operate in transmission mode often use a fluorescent light source with a 
broadband emission spectrum and a linear charge coupled device (CCD) array 
detector. These scanners permit transmission scans in up to a 48-bit red-green-blue 
(RGB) mode, e.g., 16bits per colour.64 
 
The scanner used in this experiment was an Epson V700 (Epson, NSW, Australia) 
digital scanner with software that allows for raw image data acquisition, and with no 
colour corrections made to the image; it also has a good signal to noise ratio.65 The 
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scanner should be warmed up for 30 minutes and then 10 scans made to stabilise its 
light source and ensure it is at operating temperature. 59 
 
The scanners are not flat over the entire scanning field; there may be differences of 
approximately 2% in response, with the largest being within 2-3 cm of the left and 
right sides of the scan field. To take advantage of field flatness, the films be placed in 
the centre of the scan area, away from the edge.69  
 
Scanner resolution must be set to compromise between image resolutions, file size 
and scan time, so in this study I utilised 72 dpi because a 72 dpi resolution allows for 
28 pixels per cm.   
 
It is important to save scans in 48 bit RGB tiff format because it is a lossless data 
compression technique and most software analysis is compatible with this format, 
and it also allows for split channels to obtain the required colour channel from 
subsequent analysis.  No colour correction options should be used while scanning 
because they could cause significant automatic manipulation of the OD values which 
cannot be easily tracked.64,65 
 
2.8 Film Use Protocol 
 
EBT3 film should be calibrated using a large well-characterised uniform radiation 
field. Each batch of film obtained from the distributor must be calibrated. The dose 
response curve and film sensitivity should be obtained in the dose range estimated to 
be of interest in the subsequent experiment. 
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Figure 2-3 Image of varying film colour in response to an absorbed dose. The dose 
read out from left to right: 0 Gy, 1 Gy, 2.5 Gy, 5 Gy, and 7.5 Gy. 
 
For a typical calibration and experiment carried out in this thesis, 5 pieces of film 
were irradiated at doses ranging from 1 to 14.82 Gy. The films were cut into 5.0 x 
4.0 𝑐𝑚2 pieces such that the irradiation field was considered to be uniform and 
limited within a field size of 10 × 10 cm 2.  
 
The calibration strips were chosen so they were large enough to give good statistics 
and also small enough to allow multiple samples to be cut from the same sheet of 
film. 
 
Pixel Intensity is associated with films exposure, we can relate pixel value to OD 
using equation 1-2. Each film is irradiated to a known dose value, hence OD and 
dose relationship can be obtained. Darker colour density represents higher dose.  
 
The films were positioned between two water equivalent solid water phantoms. A 
build-up of 1.5 cm thick solid water was placed between the source field and the 
irradiated sample and 10 cm thick solid water lay behind the sample as back scatter, 
in the direction of beam propagation.  The slabs were all 30 cm x 30 cm by varying 
the thicknesses (2mm to 4cm).  
 
There was no significant influence between the low and high field sizes from 
3 × 3 cm 2 up to 25 × 25 cm2 on the dose response, so only the previously mentioned 
10 × 10 cm2 configurations were implemented.13 The relative uncertainty of the 
delivered dose is around 2%, which is the standard conventional value used clinically 
when continuous quality control procedures are implemented using ionization 
chamber methods.63 
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 Each film was read after 3 warm up scans, and then readings were recorded for 3 
actual subsequent scans.  
 
After acquiring the image it was opened with ImageJ and then converted from a 16 
bit format into a 32 bit format to help extract the information required without losing 
data to size restrictions.  
 
 
Figure 2-4 Converting the image into 32 bits using Image J. 
 
The image was then split into image data sets which represented three colour 
channels, red, green and blue.  
 
Figure 2-5 Splitting the image into 3 colour channels using Image J. 
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A two-colour protocol is suggested for 3 model based radiochromic film dosimetry 
system using only the reflection mode in a dose range of 0–8 Gy; for low doses (0–2 
Gy) calibration is performed with the red channel, while for higher doses (>2 Gy) 
calibration is performed with the green channel. The dose range we want in this 
study is well above 2 Gy. As part of film validation experiments, and to validate a 
prostate boost dose exceeding 2 Gy/F, and typically around 8 Gy, the green channel 
was used for the analysis reported in this thesis. 67 
 
The green channel is used to obtain the pixel value of the selected area or line of 
interest from the film; this is done using the box or line function to outline the area of 
interest and then using the MEASURE function under the ANALYZE tab. For a box 
selection of a region of interest (ROI), the readout will be the average pixel value of 
the ROI, while for a line selection it will readout the pixel value per pixel, from the 
start to the end of the line of interest. 
 
 
Figure 2-6 Using the area selection tool on Image J to select the desired area on film. 
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Figure 2-7 Using the Measure tool on Image J to obtain the pixel value of selected 
area on film. 
 
 
The net OD is then calculated using equation: 
𝑁𝑒𝑡 𝑂𝐷 = 𝑙𝑜𝑔10[
𝐼𝑜
𝐼
]  Equation 1-2 
 
Where I is the pixel value of the film post irradiation and Io is the pixel value of the 
film pre- irradiation. 
 
To investigate the relationship between changes in optical density against known 
dose values, a calibration curve must be produced to obtain the relationship between 
the OD values obtained from film to dose. It is also important to check this curve to 
increase confidence in future results.  
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By relating the net optical density of each of the calibration strips to their known 
dose values from irradiation, a calibration curve is produced. By calculating the 
equation of the line for this calibration curve using the line of best fit function with a 
3rd degree polynomial curve in Microsoft Excel, any other unknown dose values 
within the range of the dose limit of the calibration curve can also be calculated.  
 
The accuracy of this calibration curve was then validated by irradiating film strips at 
a different depth and a different monitor units (MU) to the calibration points. Since 
MU is directly proportional to dose, this in turn equates to a different dose delivered. 
The dose to these strips was found using the calibration curve, and also calculated 
using Pinnacle TPS. The measured and calculated values were then compared to 
increase confidence in the calibration curve.  
 
2.9 Data Analysis 
 
 Film analysis was performed using ImageJ. A line profile constructed superior-
inferior plane corresponding to the Centre on the film, which would be closest to the 
prostate of each of the images. The pixel value obtained was then converted to dose 
using the calibration curve previously obtained.  
 
Figure 2-8 Marks on film corresponding to the section most anterior on the 
Rectafix®. 
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Figure 2-9 Using the straight segmented line tool in ImageJ to select the profile of 
interest. 
 
 
Figure 2-10 Using the Plot Profile function followed by the List tab on ImageJ in 
order to obtain the PV at each pixel along selected profile. 
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The dose along the same line was also calculated using pinnacle RTP in order to 
compare the measured versus calculated dose values along the rectal wall closest to 
the prostate.  
  
The measured values for the superior-inferior line profiles were then filtered using 
MATLAB and a fifth order one dimensional median filter. The function medfilt1 was 
used in MATLAB to smooth out the curve and better match the measured vs 
calculated curves; the measured curve is noisy due to film or scanner not having 
perfect uniformity, or a stain, markings or damage due to use.  
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Figure 2-11 Comparison of unfiltered film profile on top vs filtered film profile on 
the bottom 
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The measured and calculated central vertical lines for each film were then plotted as 
dose profiles on the same axis to compare the difference between the calculated vs 
measured dose for each scenario.  
 
2.10 Error Analysis and Tolerance Criteria for Acceptability  
 
When calculating tolerances for dose calculations, there are always differences 
between measurements and calculations, but these differences depend on the location 
within the beam and on patient geometry. There is no simple statement about the 
criteria of tolerances because the accuracy of dose calculations depends on the 
algorithm and the region within the beam, and the region within the patient. 
Tolerances must be analysed with this concept in mind.  
 
One method to analyse and compare calculations and measurements is to represent 
deviations statistically; there may be a tolerance set to each point value, but overall 
acceptability is not based on matching the tolerances at each point.  
 
An acceptable decision is made using confidence limits, or similar statistical data, 
and while not all the data points may meet a certain tolerance, they may still be 
acceptable as long as say, 95% of the points fall within this limit.  
 
Different people may look at the same types of tolerance data and decide on different 
values, so our expectations depend on the state of the algorithm and the type of 
situation being analysed.  
 
The deviation between the calculated and measured data can be expressed as a 
percentage of the locally measured dose:  
 
𝛿 = 100 ×
(𝐷𝑐𝑎𝑙𝑐−𝐷𝑚𝑒𝑎𝑛)
𝐷𝑚𝑒𝑎𝑛
  Equation 2-1 
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Where 𝛿 is expressed as a percentage, 𝐷𝑐𝑎𝑙𝑐 is the dose calculated at a particular 
point in the phantom, and 𝐷𝑚𝑒𝑎𝑛 is the dose measured at the same point in the 
phantom. 70 
 
A statistical assessment can be performed using a set of criteria defined by Venselaar 
et. al. on the acceptability of different tolerances for 𝛿. This is based on information 
which states that the high dose gradient regions of the beam require a different 
assessment; this can be seen in Figure 2.12 and Figure 2.13. This information is 
utilized in the IAEA TRS 430 report, which is aimed at quality assurance 
measurements of TPS.71 
 
 
Tolerance  
Homogeneous, 
simple geometry 
Complex geometry 
(wedge, 
inhomogeneity, 
asymmetry 
More complex 
geometries, i.e. 
combinations of 2 
δ1 (central beam axis 
data) high dose, 
small dose gradient 
2% 3% 4% 
δ2 build-up region of 
central axis, 
penumbra region of 
the profiles) high 
dose, large dose 
gradient 
2 mm or 10% 3 mm or 15% 3 mm or 15% 
δ3 (outside central 
beam axis region) 
high dose, small dose 
gradient 
3% 3% 4% 
δ4 (outside beam 
edges) low dose, 
small dose gradient 
30% 40% 50% 
RW50 radiological 
width 
2 mm or 1% 2 mm or 1% 2 mm or 1% 
δ50-90 (beam fringe) 2 mm 3 mm  3 mm  
 
Figure 2-12 Proposed tolerances for δ at different configurations. 71 
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Figure 2-13 Regions of δ on dose-distance profile.71 
 
The criteria acceptable for small dose gradient regions is that express  tolerances as a 
percentage, whereas in regions with a large dose gradient, the tolerance value should 
preferably be expressed in a mm shift of the relevant isodose line.72 
 
2.10.1 Suggested tolerances for individual points 
 
Venselaar et al have suggested criteria for acceptability in different test 
configurations of a beam.72  Figure 2.12 shows different acceptability criteria for a 
variety of different test configurations. 
 
It is suggested that as long as many data points of comparable situations are 
evaluated, some of the points that do not satisfy the accuracy criteria may not 
necessarily lead to a negative overall result, as long as the overall result is 
satisfactory. 
 
2.10.2 Gamma analysis  
 
Gamma analysis is a useful tool for determining how closely a treatment planning 
system and the delivered dose correlates with one another at different locations 
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around the target. For a gamma analysis to produce a positive dose correlation, the 2 
systems measured must match within a set spatial displacement and dose 
displacement tolerance. The gamma analysis can be performed in a 2D space or a 3D 
space.  
 
Distance to agreement (DTA) is calculated by locating a pixel with a known dose, 
correlating this positon to the treatment planning system, finding the corresponding 
coordinate and then measuring the distance between these two points. 73  
 
Gamma analysis incorporates this DTA with a calculation of dose difference. The 
gamma index is given by the following equation: 
 
Γ(𝑟𝑚, 𝑟𝑐) = √
𝑟2(𝑟𝑚,𝑟𝑐)
Δ𝑑𝑀
2  
+
𝛿2(𝑟𝑚,𝑟𝑐)
Δ𝐷𝑀
2   Equation 2-2 
 
The radial distance between the treatment plan pixel 𝑟𝑚 and the calculated pixel 𝑟𝑐is 
given by r. The dose difference between the two pixels is 𝛿, the dose difference 
criteria set is given by Δ𝑑𝑀
2  and the DTA criteria set is given by Δ𝐷𝑀
2  . 
 
In using this technique a tolerance level is set, i.e. if 3mm is chosen as the tolerance 
level, and if the two points between the measured and calculated pixel on TPS lie 
within a 3mm radius of one and another, the point passes the DTA. This can be seen 
as a test where the pixels either pass or fail. 
 
A gamma index of 1 and above is an indication that the test has failed. Due to the 
elliptical distribution of the gamma function, as explained in equation 2-3, a point 
where the DTA and the dose tolerance criteria are within the accepted limit may still 
fail the gamma test.  For a more detailed explanation of gamma analysis, see the 
study done by Low D. A. et. al. 74 
 
Gamma analysis was performed using Matlab software. This analysis was performed 
for a line profile because the results obtained in this study are used to compare the 
line profiles between the treatment planning system and measured dose on film.  
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Basran et. al. suggested that the tolerance for an IMRT treatment plan should be set 
at a 95% pass rate for gamma analysis with a tolerance criteria of 3%/3mm (dose 
difference/DTA), and for more complex IMRT treatments the pass rate should be 
decreased to 88%. 75  
 
T. Kairn et. al. utilised a tolerance of 3%/3mm and 2%/1mm to study complex 
IMRT, RapidArc and TomoTherapy® fields during prostate radiotherapy. 76   
 
While 3%/3mm is probably the most commonly used quantity, there is considerable 
debate about which quantities are optimal, depending on the clinical scenario. For the 
high precision treatments considered in this thesis it would be hypothesised that tight 
acceptance criteria would be of greater benefit. 
 
The plans delivered in this study are a high precision treatment which requires a high 
level of accuracy in delivery. The acceptance criteria to be studied are 3%/3mm, 
3%/1mm, 2%/1mm and 1%/1mm. 
 
2.10.3 Error Analysis 
 
 There are many sources of uncertainty that effect these measurements including 
reproducibility of the optical density measurement, photon output reproducibility and 
scanner reproducibility as well as uncertainties in the film calibration curve, effect of 
the film positioning and small SSD variations between the applications, temperature 
and humidity effects, dust, fingerprints, scratches and the fitting function. 67, 82 
 
The effects of scanner performance, variations in the linear accelerator performance 
and any differences the film may have intra sheet, are error corrections that cannot be 
made because this  is a statistical analysis of data and varies with the time and 
environmental changes.   
 
Any errors in the film manufacturing process, set up errors, human errors, non-
uniformities in the light field of the scanner and storage of the film are random errors 
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that cannot be corrected for. Because the differentiating factor when calculating this 
uncertainty is that it is not based on statistical data, these errors may be corrected or 
possibly eliminated.  
  
Uncertainties were minimised by following a strict protocol with the use of film and 
its analysis; as discussed in previous sections.  
 
The calibration curve measurements were repeated 3 times and the average of all 3 
data was used to construct a mean curve. The error of each dose point was calculated 
using a t-test with a confidence interval of 95%. 
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3 Calibrating Film 
 
3.1 Aim 
 
To measure the dose at the rectal wall during a prostate boost high precision 
treatment, EBT3 film was calibrated according to the batch being used, and then 
partially wrapped around a Rectafix® device.  
3.2 Materials and Method 
 
The Gafchromic EBT3 film used in all the following experiments is from lot number 
12171302, Ashland speciality Ingredients, NJ, USA. 
 
The films were irradiated in a solid water phantom at Dmax 100 SSD with 1.5 cm 
build up and 10 cm underlying backscatter material. The measurement at Dmax 
ensured that the MU recorded was equal to the dose in units of cGy where 1 MU is 
equal to 1 cGy. The 10 cm underlying backscatter material ensured there was enough 
Solid Water producing back scatter to meet requirements. The irradiation field was 
10 x 10 cm2 and was considered to be uniform; this set up is shown in Figure 3-1. 
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Figure 3-1 Film calibration set up.  
 
Film was analysed using the method outlined in sections 2.7, 2.8 and 2.9. The green 
channel was used to analyse dose values that are well above 2 Gy, but for doses 
around 2 Gy and below, the red channel is better suited for data analysis.  
 
The film is left for 48 hours to develop and then scanned in accordance with the 
protocol previously outlined.  
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The OD for the green and red channels was measured separately, and then the net 
OD is calculated using Equation 2.1. This ensures that any variation of pre irradiation 
OD between each strip of film is accounted for. 
 
3.3  Green Channel Calibration  
 
 
Figure 3-2 Calibration curve using the green channel 
 
Any dose values below 2 Gy were not included in the green channel calibration 
curve because this is not favourable, as outlined in section 2.8. 
 
The OD for each point is averaged and then an error analysis using the student t-test 
is carried out to give the possible variation of each point within a confidence interval 
chosen to be 95%.  
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The error for each dose point was studied according to the calibration curve in Figure 
3-2, and the error of each point is as follows. 
 
Dose (Gy) Dose CD (Gy) 
2.65 ±0.014 
5.30 ±0.024 
7.95 ±0.065 
10.59 ±0.14 
12.71 ±0.21 
14.83 ±0.29 
 
Table 3-1 Errors calculated for each dose point in the green channel using the t-test 
with a confidence level of 95% 
 
To find a mathematical relationship between net OD and dose that will relate other 
values of net OD within the range measured to the value of a dose, a line of best fit 
with a 3rd degree polynomial fit was overlaid onto the graph using Microsoft Excel 
by fitting a curve of best fit (add trend line function). The equation was then obtained 
to be: 
𝐷 = 1.5553𝑥3 + 36.64𝑥2 + 7.5077𝑥 Equation 3-1 
 
A confidence level >95% is also satisfied because the confidence of this line of best 
fit to the green calibration curve is 99.9% and the line can be accepted as a proper fit.  
 
A calibration curve for the red channel was also calculated, as shown in Figure 3-3. 
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3.4 Red Channel Calibration 
 
 
Figure 3-3 Calibration curve using the red channel 
 
To achieve a straight line for the calibration curve, only the film strips within the 
relevant dose range for the red channel are used. The net OD is then calculated using 
Equation 3-2. 
 
Dose (Gy) Dose CD (Gy) 
0.53 ±0.014 
1.01 ±0.0086 
2.65 ±0.0097 
Table 3-2 Errors calculated for each dose point in the red channel using the t-test 
with a confidence level of 95% 
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A line of best fit using a 3rd degree polynomial in Microsoft Excel was again utilised 
to obtain a relationship between the net OD and dose. 
 𝐷 = 5.8198𝑥2  +  12.835𝑥 −  0.2873 Equation 3-2 
 
A confidence >95% is also satisfied because the confidence of this line of best fit to 
the red calibration curve is 100% and the line can be accepted as a proper fit.  
 
3.5 Validation of Calibration  
 
To validate the calibration curve, 2 strips of film were placed inside 5 cm deep solid 
water with 10 cm underlying backscatter material, which was then placed in the 
beam at 100 SAD with a 10 x 10 cm2 size field.  One strip was exposed to 450 MU 
and the other to 750 MU; this set up is shown in Figure 3-4. 
 
 
 
49 
 
Figure 3-4 Set up used to calibrate the test film. 
 
The film was analysed using protocol described previously and the green channel 
calibration. The dose the film should have measured was also calculated using 
Pinnacle TPS, and then the calculated and measured dose was compared. 
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The difference in error was calculated using the equation: 
 
%𝐸𝑟𝑟𝑜𝑟 =
𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑−𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑
|𝐶𝑎𝑙𝑐𝑢𝑎𝑙𝑡𝑒𝑑|
 Equation 3-3 
 
 
The dose received by each film was: 
 
 
MU Dose Measured (Gy) Dose Calculated (Gy) % Error 
450 3.81 3.80 0.3 
750 5.65 5.70 0.9 
Table 3-3 Dose measured and calculated on calibrated test film with the resulting 
error.  
 
By making use of the criteria of acceptability in the IAEA TRS 430 report71, for a 
homogenous field at the central axis, any error below 2% is acceptable. Since the 
error between the calculated dose and the one measured using the calibration 
Equation 3-1 is within this limit, as seen by Table 3-3, the protocol used for film 
analysis and the calibration equation obtained can be used within a 2% tolerance.   
 
3.6 Discussion  
 
The confidence gained from using the protocol and from calibrating this batch of 
film means that any increase in dose difference is specific to that delivery task and 
not to any major error in dose measurement.   
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4 Non Modulated Field Experiments 
 
4.1 Aim 
 
Although calibration was successful, moving forward to the desired test measuring 
dose in a high precision prostate boost plans in VMAT and TomoTherapy® is 
complex because both are multi leaf collimated rotational IMRT delivery techniques. 
 
4.2 Materials and Methods  
 
The CIRS phantom was used because it is non-homogenous due to the Rectafix® 
and its polyoxymethylene sleeve is denser than the tissue equivalent solid water. 
  
The Rectatix® device with polyoxymethylene sleeve inserted into the CIRS phantom 
becomes non-homogenous due to density difference.  
 
The film used in the simple field experiments was flat, but it was folded into a semi-
circle to conform to the Rectafix® device with the Rectafix® sleeve fitted over the 
film and inserted into the CIRS phantom.  
  
Furthermore, a 1 dimensional profile can be extracted from the measurement film 
and matched to the TPS to validate the accuracy of the TPS at the rectal wall with the 
Rectafix® inserted.  This is the key to these experiments. 
 
To validate every feature in this experimental set up would help in measuring the 
desired high precision prostate boost plan, so a series of tests where each step is 
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divided into simpler scenarios was carried out to increase confidence in the 
experimental set up. 
 
This film does spring back and it resists bending into small radius, so it can only be 
shaped if held firmly in place; this characteristic means it cannot be wrapped 
completely around the Rectafix®, as shown Figure 4-1. Furthermore, the cut edge 
can be damaged so it should be kept 1.5 mm away from the other edge; this also 
reduced the area of rectal volume that was analysed. Since we are only interested that 
section of film closest to the prostate, in the higher dose region this did not hinder the 
project.  
 
 
 
 
Figure 4-1 Rectafix®, film and sleeve set up showing the sleeve holding the film in 
place around the Rectafix®.  
 
The film used to wrap around the Rectafix® should be large enough to give good 
data and still be able to wrap around the Rectafix®. In this case a strip of film 4.5 cm 
wide by 11 cm long was a good compromise because it covered the entire length of 
the Rectafix®.  
 
Each film was marked at the centre of the most superior edge of the Rectafix® 
device because it reciprocates the area closest to the rectal wall and the prostate; that 
area of the rectal wall that would receive the highest dose.  
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Figure 4-2 Rectafix®, sleeve and film set up placed inside CIRS phantom. 
 
The beams traversed different thicknesses of material, from various angles and 
different densities. The film was wrapped around the Rectafix®, and the stress of 
sliding in and out of the sleeve was also tested. 
 
First, 12x12 cm2 film is placed inside a solid water phantom with a 10 cm build up 
and 10 cm underlying backscatter material, and then irradiated by a 6 MV beam with 
5x5 cm2 field with 3 dose fields from 3 angles - 270°, 0° and 90°. Each beam is the 
same weight so 300 MU is delivered with each run at 100 SAD, as shown in Figure 
4-3. 
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Figure 4-3 Water phantom 3 field set up. 
 
In the next step, 12x12 cm2 film was placed inside a solid water phantom with a 10 
cm build up and 10 cm underlying backscatter material. This experiment was carried 
out with a 5MV arc beam and 5x5 cm2 size fields, 180° continuous movement 
around the phantom starting from 270° and ending at 90° at 100 SAD. In total 600 
MU was delivered. This set up is shown in Figure 4-4. 
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Figure 4-4 Water phantom arc beam set up. 
 
  
These 3 beam configurations were then implemented again with the solid water 
phantom swapped for the CIRS phantom set up shown in Figure 4-2. The CIRS 
phantom is aligned so that the gantry at the centre of the Rectafix® is 100 SAD. This 
set up is shown in Figure 4-5. 
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Figure 4-5 CIRS phantom 3 beam set up. 
 
 The arc beam set up was implemented with the CIRS phantom set up utilised as 
shown in Figure 4-2. The CIRS phantom is aligned so that the gantry to the centre of 
the Rectafix® is 100 SAD. This set is shown in Figure 4-6. 
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Figure 4-6 CIRS phantom arc beam set up 
 
These experiments were carried out and the protocol for film analysis was followed 
as discussed previously in section 2.9. 
 
Image software was then used to extract a 1d line profile between the 2 marks that 
correspond to the centre of the image, or in the superior-inferior direction in case of 
the CIRS phantom and Rectafix® set up in Figure 4-2. The pixel values were then 
converted to OD and then to dose using the calibration curve. 
 
The dose obtained is smoothed using a 5th order median filter on Matlab. This was 
performed twice for each profile to remove noise spikes in the film because the pixel 
value at each point differed slightly before a dose is given or any minor scratches that 
resulted from taking the film out of the box to when it was scanned. The 
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corresponding dose profile for each measurement was also extracted from the TPS, 
and then the measured and calculated line profiles were compared by superimposing 
both profiles. 
 
The accuracy between the measured and calculated profiles was checked by using 
Equation 2-3 to check the percentage difference between each and then validating the 
result using the acceptance criteria for a dose profile, as outlined in the report TRS-
430.71 
 
4.3 Results 
 
 
Figure 4-7 Film and TPS dose profiles using Solid Water 3 beam set up. 
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Figure 4-8  Film and TPS dose profiles using CIRS phantom 3 beam set up. 
 
 
 
Figure 4-9 Film and TPS dose profiles using Solid Water arc beam set up. 
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Figure 4-10 Film and TPS dose profiles using CIRS phantom arc beam set up. 
 
 
Configuration δ1 δ2 δ3 δ4 
3 fixed field solid water phantom 0.2% 2.6% 0.7% 15.2% 
3 fixed field CIRS phantom 2.3% 6.7% 2.3% 28.0% 
Arc field solid water phantom 0.9% 13.6% 1.5% 14.1% 
Arc field CIRS phantom 1.4% 1.7% 1.3% 25.5% 
Table 4-1  Tolerance criteria of sections of the dose profiles obtained from IAEA 
TRS-430. 70  
 
4.4 Discussion 
 
By using the acceptance criteria limits set for a simple geometry homogenous 
phantom in the central beam for the solid water set up, and the acceptance criteria for 
a complex geometry non-homogenous limits for the CIRS phantom with the 
Rectafix® set up, it was noted that the error at each point outlined in the TRS-430 
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report and the profiles are within the limits allowed.71 This means the measured 
profiles are an acceptable match to the TPS. 
 
The δ2 measurement for the arc field solid water measurements are outside the TRS-
430 tolerances for dose difference, but are accepted due to being within the DTA 
measurement.  
 
Figure 6.3 shows that an equal amount of solid water was traversed by the beam 
before it reached the central profile of the film, although most of the dose was 
delivered edge on to the film. Each dose is overlapped by 3 separate beams and a 
high uniform dose with a high dose gradient at the penumbra region is delivered.  
 
 This result means the line profile can be extracted and successfully matched with the 
TPS, and it also indicates that the film can also measure the dose from edge on.  
 
Figure 4-4 shows that the beam traversed varying thicknesses of phantom and from 
many different angles; this also occurred at a high dose and high dose gradient at the 
penumbra. 
 
The good match between the measured and calculated profiles indicates that the film 
can measure a dose accurately from many angles and through varying thicknesses of 
material, and the continuous beam had no negative effect on the dose measured.  
 
 This result is important because the CIRS phantom is elliptical and the film will be 
measuring a dose from materials with varying thicknesses.  
 
The set ups shown in Figures 4-5 and 4-6 show that the film and the TPS matched 
well, as also shown in Figures 4-8 and e 4-10.  
 
This indicates that the non-homogenous composition, and any damage to the film by 
inserting the sleeve or stress caused by bending, had no negative impact on 
measuring the dose. Moreover, the shape of the film is also not a factor when 
measuring the dose. 
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The dose between the solid water and the CIRS phantom set ups are different even 
though the same plan is delivered due to the film in the CIRS phantom sitting on top 
of the Rectafix®  – while 100 SAD was taken as the centre of the Rectafix®.  
 
Since a line profile is being measured, any rotation or tilt in positioning the 
Rectafix® will impact on the profile measured because the dose is being measured in 
a high dose gradient. By making use of the fiducials and room lasers pre irradiation, 
the Rectafix® was aligned precisely into the correct positon.   
 
 
Figure 4-11 Stain or damage marks on film  
 
Figure 4.11 shows there are spikes in the graph at random sections that relate to a 
stain, a scratch, or a mark on the film; they are therefore irrelevant to the overall 
outcome of these experiments.  
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5 VMAT Experiment 
 
5.1 Aim 
 
Having refined the experimental technique with the simple 3 field and non-
modulated arc beam experiments, the next step was to measure the dose using a 
prostate high precision boost treatment.  
 
5.2 Materials and Method 
 
A plan was created by superimposing an existing patient plan for a high precision 
prostate boost therapy using VMAT, onto the CIRS phantom with the Rectafix® 
insertion using Pinnacle TPS. This allowed for contours of volumes such as the PTV, 
the clinical target volume (CTV), as well as organs and critical structures to be 
copied onto the CIRS phantom. The set up is described in Figure 4-2.  
 
 
 
Figure 5-1 VMAT plan view with isodose lines obtained from Pinnacle TPS. 
 
64 
The CTV includes the prostate and extraprostatic disease, as well as an extracapsular 
extension or seminal vesicle invasion. The PTV was set for a 5mm extension to the 
CTV margin in every direction but the posterior margin, which was set for a 3mm 
extension.  The rectum in this plan is curved, while the rectal wall utilised on the 
phantom is straight, so an insert on the CIRS head and neck phantom is used to 
replicate a rectum. The dose measured with film to TPS data has no negative impact 
on the scope of this thesis.  
 
The plan parameters were set in accordance with the phase II Prometheus trial where 
a high precision boost for prostate cancer was delivered with a hypo-fractionated 
schedule of 21.1 Gy in 2 fractions. The prescribed dose is set so that 90% of the dose 
(19 Gy) of the target maximum covers a minimum of 95% of the planning target 
volume (PTV).  To achieve a sharp fall off in the dose, an in homogenous 
distribution is acceptable. 
 
The objective of this treatment plan is to limit the dose to the rectum to 14-16 Gy, 
with the maximum dose occurring in the overlap region between the rectum and 
PTV, but there is a chance that the PTV adjacent to the rectal volume may receive a 
minimum dose of 16 Gy while the urethra would receive a maximum dose of 21 Gy. 
 
The phantom was aligned using the fiducial markers and room lasers, and then the 
experiment was repeated twice. 
 
The phantom was then shifted 3 mm in the anterior direction and the dose measured 
once again using the same set up. 
 
The film was then scanned according to the protocol outlined previously in section 
2.8. A line profile was extracted from each of the 3 films in the superior-inferior 
direction on the most anterior section of the Rectafix®, converted to net OD using 
Equation 2-1 and then to a dose using Equation 3-1. The profile was then filtered 
twice using the medfilt1 function on MATLAB with a dimension of order 5, and then 
then TPS was used to extract a line profile corresponding to the same position. The 
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calculated and measured profiles at the rectal wall - Rectafix® interface were then 
superimposed with each other. 
The calculated and measured profiles were then analysed with a gamma analysis by 
calculating the dose on the measured profile and the TPS at 1 mm intervals, so that 
each profile could be assessed at the same position on the curve. Matlab was used to 
perform the gamma analysis, and γ < 1 was accepted as a pass while a γ ≥ 1 was 
taken to be a fail.  
 
The gamma analysis was then plotted as a visual representation of how well each 
figure matched the TPS. A plot comparing the dose profiles measured between the 
rectal wall and a 3mm shift in the anterior direction was also produced.  
 
 C. Huet et. al. have already investigated the variation in mean pixel value on a 
neutral film as a function of the number of scans on different days and concluded that 
measurements were not reproducible. 69 This along with a film variation inter sheet 
and an inter batch render the film not reproducible for dose measurement modality.  
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5.3 Results and Discussion 
 
Figure 5-2  Film measured against TPS calculated VMAT delivery profile 
 
In utilising the 3%/3mm acceptance criteria, 100% of the points passed the gamma 
analysis, as shown in Figure 5-3. 
 
Figure 5-3 3%/3mm gamma analysis of Figure 5-2 VMAT delivery. Pass rate: 100% 
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 The DTA was then reduced and the 3%/1mm acceptance criteria measured. The pass 
rate for the selected criteria is 100%, which means the gamma parameters can be 
tightened even further. This is shown in Figure 5-4. 
 
 
Figure 5-4 3%/1mm gamma analysis of Figure 5-2 VMAT delivery. Pass rate: 100% 
 
The gamma parameters were then changed to 2%/1mm and a failed gamma point can 
be observed. The pass rate for this test was 98.8%, which is still within the 
acceptable limit. This is shown in Figure 5-5. 
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Figure 5-5 2%/1mm gamma analysis of Figure 5-2 VMAT delivery. Pass rate: 98.8% 
 
The gamma parameters were tightened again to determine how tight they can be 
made before the pass rate is unacceptable at <95%. The parameters this time were 
1%/1mm and the pass rate was 89.2% which is below the minimum acceptable value 
of 95%. This is shown in Figure 5-6. 
 
Figure 5-6 1%/1mm gamma analysis of Figure 5-2 VMAT delivery. Pass rate: 89.2% 
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This result indicates that gamma analysis can only be tightened to 2%/1mm utilising 
this method. For a further investigation, the same gamma parameters were studied 
through all the film vs TPS comparisons. This will be analysed at a later point in a 
table format.  
 
To determine the reproducibility of the measured data, 2 measurements were 
obtained from each treatment plan, and then the VMAT delivery was repeated. A 
comparison between the repeat film measurement and the TPS is shown in Figure 5-
7. 
 
 
Figure 5-7 Film measured against TPS calculated VMAT second delivery profile 
 
A gamma analysis was then carried out utilising the acceptance criteria 3%/3mm, 
3%/1mm, 2%/1mm and 1%/1mm which are shown+ in Figure 5-8, Figure 5-9, 
Figure 5-10, and Figure 5-11 respectively.  
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Figure 5-8 3%/3mm gamma analysis of Figure 5-7 VMAT delivery Pass rate: 100% 
 
 
Figure 5-9 3%/1mm gamma analysis of Figure 5-7 VMAT delivery Pass rate: 100% 
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Figure 5-10 2%/1mm gamma analysis of Figure 5-7 VMAT delivery Pass rate: 
98.3% 
 
 
Figure 5-11  1%/1mm gamma analysis of Figure 5-7 VMAT delivery Pass rate: 
89.2% 
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 To compare the initial and repeat measurements obtained from the VMAT delivery, 
the two film measurements were graphed together to give the visual representation 
shown in Figure 5-12. 
 
 
Figure 5-12 VMAT profile and VMAT profile repeat comparison 
 
A gamma analysis utilising 2%/1mm acceptance criteria was then carried out to 
compare both film measurements. This can be seen in Figure 5-13. A pass rate of 
100% was obtained. 
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Figure 5-13 2%/1mm gamma analysis, VMAT profile and VMAT profile repeat. 
Pass rate: 100% 
The reproducibility comparison shows a good gamma analysis with 100% pass using 
2%/1mm acceptance criteria  
The dose measured along the rectal wall was then compared to the dose measured 
with a 3 mm anterior shift to determine what the outcome of a positional error would 
have on the results. This is shown in Figure 5-14. 
 
Figure 5-14 VMAT rectal wall profile against 3 mm anterior shifted profile  
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The film measurement with a 3mm anterior shift resembles the TPS at the rectal wall 
at the initial portion of the curve, but then deviates markedly. An error such as this 
would incur a large variation in the shape of the curve because the film is placed in 
an area with a large dose gradient so it is very unforgiving of positional errors. 
 
Moreover, if the rectal wall was misplaced 3mm anterior into the higher dose region 
then a larger portion of the rectal wall would receive a substantially higher dose and 
hence increase the risk of greater rectal toxicity. 
 
None of the gamma points in Figure 5-2 failed, however the initial portion of the 
curve up to 1.6 cm had the highest gamma value at 0.88; this corresponds to that 
section of the curve with the highest dose gradient.  
 
A spike in gamma occurred in areas with a rapid change in the dose gradient.  
 
There is a similar trend in Figures 5-3, 5-4, and 5-5 but in Figure 5-5 the gamma 
failed in the 1 cm to 1.5 cm range; this plan is still considered to be acceptable 
because 95% of the points passed the gamma test. 
 
High dose gradients are a worse match because the dose changed rapidly over a short 
distance, causing the dose threshold component of the gamma analysis to quickly fall 
outside the range.  This was explained by M. Stasi 77, where even if a poor pass rate 
is present in a high dose gradient, the plan may still be accepted. Gamma analysis is 
open to interpretation in the region to which it is applied.    
 
Although a spike in the gamma is visible in Figure 5-3 in the same region, it still 
passes at 100% of the points.  
 
This difference can be contributed to either a slight positional error during analysis, 
or starch or stain on a particular region, as explained previously in Figure 4-11.  
 
The good match in the measured and calculated profiles and the high pass rate of 
gamma seen in Figures 5-3, 5-4, and 5-5 show that a good match of calculated and 
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measured dose profiles can be obtained on the anterior rectal wall. These repeat 
measurements also prove that the results can be successfully duplicated.  
 
The objective of the treatment plan is to limit the dose to the rectum to 14-16 Gy, 
with the maximum dose occurring in the overlap region between the rectum and PTV 
because the PTV adjacent to the rectal volume may receive a minimum dose of 16 
Gy. 
The region that received the highest dose is visible at 3.92 cm along the profile with 
a dose of 11.95 Gy. Since the prescription will be delivered in 2 fractions, the rectal 
wall will receive double this dose, 23.90 Gy. This is substantially higher than the 
limit of 14-16 Gy to the rectum that was prescribed and hence will need further 
investigation before treatment can continue.  
 
5.4 Conclusion 
 
Successfully measuring the dose profile at the anterior rectal wall in a prostate boost 
high precision VMAT plan has proven that the method used is successful while in 
this pilot the phantom study detected shifts of 2mm with a dose difference of 1%.  
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6 TomoTherapy® Plan Measurements  
 
 
6.1 Aim 
 
The aim is to use the same method employed for VMAT delivery in chapter 5, in a 
prostate high precision boost treatment delivered with TomoTherapy®.  
 
6.2 Materials and method  
 
The TomoTherapy® Hi·Art II TPS v.4.2.2 uses a collapsed cone algorithm to 
calculate the dose to medium. 
 
The TomoTherapy® plan was created by superimposing the same patient treatment 
plan outlined in chapter 5.  This allowed for contours of volumes such as the PTV 
and clinical target volume (CTV), as well as organs and critical structures to be the 
same as the VMAT case. The set up described in Figure 7.1 was used.  
 
 
The same patient data utilised in chapter 5 was set for a high precision prostate boost 
with TomoTherapy® was used and optimised for the CIRS phantom by utilising a 
2.00 x 2.00 2.00 cm3 dose grid. Each slice was 2 mm thick for calculation. 
 
The same plan parameters and treatment plan objectives were used as with VMAT, 
outlined in Section 5.2. 
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Without a dose control system to maintain a constant dose output within the limit of 
2%, the output of the TomoTherapy® unit drops as a function of time.78,79 Since the 
output of the machine fluctuates more than 2% if the beam is on for more than 7 
minutes, the fraction is split into 3 parts and is delivered in 3 passes so that each pass 
is less than 7 minutes. To achieve this result, the clinical plans are modified to 
include 6 fractions instead of 2.  
 
The CIRS phantom and Rectafix® set up seen in Figure 4-2 were again utilised for 
these experiments. The phantom was aligned using the room lasers, the film was 
wrapped around the Rectafix® and the anterior section marked, the sleeve was then 
pushed over the Rectafix® and then inserted into the CIRS phantom. The Rectafix® 
was aligned using the room lasers, and then its position was verified using a pre-
treatment megavoltage (MV) CT scan by the TomoTherapy®  unit at approximately 
3.5 MV 80 . The fiducials can be seen and are used as a verification tool in the 
process.  
 
 
 
 
Figure 6-1 TomoTherapy® plan view with isodose lines obtained from 
TomoTherapy® planning station. 
 
The first two passes were measured using the film at the rectal wall interface, and 
then the set up was shifted 2mm in an anterior direction into the high dose region, 
and then another measurement was taken using film. 
 
The film was then analysed using the protocol outlined in Section 2.8.  
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 A line profile was extracted from the most anterior section, in the superior-inferior 
direction of the Rectafix® device by making use of the markings on the film placed 
prior to irradiation. The PV obtained was then converted to OD and then to dose, by 
making use of the calibration equation 3-2. The red channel calibration curve was 
utilised as the dose range most suited to the dose measured by the measurements. 
 
 A 5th order median filter was then applied to each curve twice, using Matlab, to 
reduce any noise and small scratches and smooth the curves.  
 
 A line profile was then extracted using the TomoTherapy® TPS at the anterior edge 
of the Rectafix®, in a superior-inferior direction. A profile 2 mm anterior to the 
Rectafix® was also extracted in the superior-anterior direction. 
 
The measured and calculated profiles at the anterior edge of the Rectafix® were then 
superimposed. The dose profiles measured and calculated 2mm anterior to the 
Rectafix® were also superimposed. The measured dose profile of the first pass at the 
rectal wall and the 2mm anterior shift was also compared.  The measured profiles 
and calculated profile doses were then calculated at 1mm increments to determine 
the dose of each profile at the same distance. 
 
This information was then used to carry out a gamma analysis of each point using 
MATLAB; this analysis was carried out with the same gamma parameters used 
previously, 3%/3mm, 3%/1mm, 2%/1mm and 1%/1mm, where γ < 1 was accepted as 
a pass and γ ≥ 1 was taken to be a fail.  
 
 
 
 
 
 
 
 
 
79 
6.3 Results and Discussion 
The measured film results were compared to TPS data, as shown in Figure 6-2. 
 
Figure 6-2 TomoTherapy® Film and TPS profiles. 
 
The film results and TPS were compared by again utilising the gamma analysis. A 
further gamma analysis was carried out utilising acceptance criteria 3%/3mm, 
3%/1mm, 2%/1mm and 1%/1mm, as shown in Figures 6-2, 6-3, 6-4, and 6-6 
respectively.  
 
The pass rate for the gamma analysis for 3%/3mm acceptance criteria are 100%, and 
this is shown in Figure 6-3.  
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Figure 6-3 3%/3mm gamma analysis of Figure 6-2 TomoTherapy® delivery Pass 
rate: 100% 
 
The criteria were tightened again to 3%/1mm.  Figure 6-4 shows that gamma 
analysis failed at ~6.1 cm along the profile which corresponds to a “bump” in Figure 
6-2, most likely indicating damage or stain on the film at this location which altered 
the PV obtained. The gamma analysis also failed ~7.8 cm to 8 cm along the film 
profile. 
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Figure 6-4 3%/1mm gamma analysis of Figure 6-2 TomoTherapy® delivery Pass 
rate: 98.5% 
 
The same pattern can be seen in the acceptance criteria 2%/1mm with more points 
failing, dropping the pass rate to 97.3%. The gamma analysis failed at ~6.1 cm along 
the profile and ~7.8 cm to 8 cm along the film profile. There is also a new point 
which failed at ~4.9 cm along the profile. In Figure 6-2 this section can be visually 
seen to correspond to another “bump” on the profile, which may indicate damage or 
stain on the film at this particular location.  
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Figure 6-5 2%/1mm gamma analysis of figure 6-2 TomoTherapy® delivery Pass 
rate: 97.3% 
 
The pass rate here fell below the 95% acceptance level at 1%/1mm acceptance 
criteria, with added points at the start of the profile of  ~3.2 cm, 3.6 cm to 3.9, 4cm, 
4.9cm, 5.1 cm, 5.3 cm, 5.5 cm, 6.1 cm and 7.8 cm to 8 cm.  
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0 1 2 3 4 5 6 7 8
G
am
m
a
Distance (cm)
 
83 
 
Figure 6-6 1%/1mm gamma analysis of figure 6-2 TomoTherapy® delivery Pass 
rate: 85.0% 
 
The TomoTherpay® plan measurement was then repeated and the same gamma 
analysis carried out. The film measurement repeated against the calculated TPS 
profiles can be compared in Figure 6-7.  
 
Figure 6-7 TomoTherapy® repeat film measurement against TPS profile. 
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Figure 6-8 3%/3mm gamma analysis of Figure 6-7 TomoTherapy® delivery Pass 
rate: 100% 
 
Figure 6-9 shows that a 3%/1mm acceptance criteria produced a pass rate of 100%, 
but when compared to the measurement seen previously in Figure 6-4 with a pass 
rate of 98.5%, the repeat measurement is noticeably more accurate. In Figure 6-7, the 
same number of “bumps” on the film measurement is also not apparent, as seen in 
Figure 6-2; this may be due to an increased efficiency and skill in the use of film at 
this point, leading to less human error when handling the film. 
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Figure 6-9 3%/1mm gamma analysis of Figure 6-7 TomoTherapy® delivery Pass 
rate: 100% 
 
The gamma analysis shown in Figure 6-9 is a 100% pass for 2%/1mm acceptance 
criteria, which indicates a better match than Figure 6-5 which has a pass rate of  
97.3%; this may also be due to increased skill in the phantom set up and handling 
film while carrying out this experiment.   
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Figure 6-10 2%/1mm gamma analysis of Figure 6-7 TomoTherapy® delivery Pass 
rate: 100% 
 
The 1%/1mm gamma analysis shown in Figure 6-10 has a pass rate of 91.00% with 
the majority of gamma points failing ~3cm along the profile. The measured profile 
deviates to a slightly lower dose than the TPS, possibly due to error when analysing 
the film, or damage and stain that may have affected the PV obtained in that section.  
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Figure 6-11 1%/1mm gamma analysis of Figure 6-7 TomoTherapy® delivery Pass 
rate: 91.0% 
To compare the two TomoTherapy® measurements obtained, both the profiles were 
plotted together as shown in Figure 6-12. 
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Figure 6-12 TomoTherapy® profile and TomoTherapy® profile repeat plot 
comparison 
A 2%/1mm gamma analysis was then carried out, as shown by Figure 6-12, and 
produced a pass rate of 99.8% 
 
 
Figure 6-13 2%/1mm gamma analysis between the TomoTherapy® profile and the 
TomoTherapy® profile repeat.  Pass rate: 99.8% 
 
0
0.5
1
1.5
2
2.5
3
0 1 2 3 4 5 6 7 8
D
o
se
 (
G
y)
Distance (cm)
TomoTherapy® TomoTherapy® Repeat Measurement
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0 1 2 3 4 5 6 7 8
G
am
m
a
Distance (cm)
 
89 
When the measured profiles are compared to each other, a miss match is visible at 
the end of the profiles ~7.9 cm along the profile. 
 
Since this dose was delivered in one out of three  passes for the single fraction, the 
dose delivered to the rectal wall will the six times that shown on the extracted 
profiles shown in Figure 6-12.  
 
The objective of the treatment plan is to limit the dose to the rectum to 14-16 Gy, 
with the maximum dose occurring in the overlap region between the rectum and PTV 
because the PTV adjacent to the rectal volume may receive a minimum dose of 16 
Gy. 
 
The maximum dose delivered to any single point on the rectal wall will be 16.04 Gy, 
as indicated at the location 2.6 cm along the profile; this is within the dose objectives 
set for the treatment plan.  
  
A measurement was obtained 2 mm anterior to the rectal wall and then compared to 
the TPS, as shown in Figure 6-14. 
 
Figure 6-14 TomoTherapy® 2mm anterior shifted film and TPS profiles. 
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A gamma analysis was carried out with 3%/3mm acceptance criteria and it revealed a 
100% gamma pass rate. This indicates that as long as the position of the film is 
known, the relevant profile can be extracted from the TPS and matched with the 
measurement obtained by utilising film. 
 
 
Figure 6-15 3%/3mm gamma analysis of Figure 6-14. Pass rate: 100%. 
 
Comparing the film dose measured at 2mm anterior shifted position to the TPS at the 
rectal wall, as shown in Figure 6-16, indicates that the initial build-up of dose 
matches, but the measured profile gives a larger dose to a larger area. This will 
probably increase rectal toxicity and may cause the complications discussed 
previously in the NTCP model. 
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Figure 6-16 TomoTherapy® measured profile at rectal wall against 2 mm anterior 
shifted measurement. 
 
6.4 Conclusion 
 
Successfully measuring the dose profile at the anterior rectal wall in a prostate boost 
high precision TomoTherapy™ plan has proven that the method is successful and in 
this pilot phantom study, 2mm shifts were detected with a dose difference of 1%.  
 
  
 
 
 
 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
3
3.5
0 1 2 3 4 5 6 7 8
D
o
se
 (
G
y)
Distance (cm)
TPS at rectal wall Film 2mm Anterior Shift
 
92 
 
 
 
 
7 Discussion 
 
 
The measured profiles were only extracted from the anterior edge of the Rectafix®  
in the superior-inferior direction because this is the area of most interest in studying 
the dose received by the rectal wall, being the closest to the PTV and hence the area 
of rectal wall where most of the dose is deposited.   
 
 Due to the nature of the film, the edges near the border suggested not to be used for 
measurements due to damage by cutting, a dose map of the full rectum could not be 
obtained, but a large portion was easy to obtain.  
 
That the film covers a wide area of the rectal wall opens up the possibility of 
measuring a dose at any point, profile, or plane covered by the film.  
 
The method used to obtain the profiles in section 2.8 can be used to obtain multiple 
parallel points along the film and around the Rectafix® on the TPS; this to obtain the 
full 2D dose coverage of the rectal wall in line with the film.  
 
The gamma analysis was for a 2D profile, while the plan delivered is for a 3D 
patient; this eliminates a spherical check of the DTA factor and limits it to the 2D 
plane instead; this also removes some of the power of the gamma analysis.  
 
 When the gamma acceptance criteria of 3%/3mm was used no points failed, which 
indicated that the chosen parameters could not detect any significant difference in the 
compared profiles.  
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As the acceptance criteria became tighter it became apparent that although the same 
measurements were repeated, the gamma analysis showed some difference between 
them. The most suitable criteria for a high precision boost treatment was 2%/1mm, 
and this is some of the tolerance suggested from the literature. 76 All the films were 
above the minimum pass rate of 95%. 
 
The 1%/1mm acceptance criteria produced an underwhelming pass rate. The pass 
rate for complex fields of 88% suggested by Basran et. al. 75 was only reached on one 
of the two runs for each VMAT and TomoTherapy® deliveries. This level of 
precision is at the current limit of accuracy for this delivery.  
 
 VMAT  VMAT 2 TomoTherapy® TomoTherapy® 2 
3%/3mm 100% 100% 100% 100% 
3%/1mm 100 99.01 98.51 100 
2%/1mm 98.76 98.23 97.26 100 
1%/1mm 89.22 85.97 85.04 91.02 
Table 7-1 Summary of gamma pass rates obtained 
 
The dose delivered by VMAT will exceed the limit of the prescribed dose to the 
rectal wall, although this method successfully detected a 2 mm shift. This affords an 
opportunity to make necessary adjustments before treatment is continued and in turn 
avoids any unwanted rectal toxicity. 
 
The TomoTherapy® plan was within the dose limit prescribed to the rectal wall, so 
in this case the treatment is safe and the second fraction can be delivered with 
confidence because it could detect a 2 mm shift. 
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8 Conclusion and Recommendation 
 
 
We can now go back to answer some of the research questions set previously: 
 
i. Can EBT3film be positioned on Rectafix® device such that it simulates a 
dose at the rectal prostate interface? 
 
It was found that positioning film around a Rectafix® device is a viable way of 
measuring the dose to the rectal wall in VMAT and TomoTherapy® high precision 
prostate boost treatments. Indeed it is evident that comparing the dose at the rectal 
wall obtained from TPS to the measured dose utilising film deployed on the 
Rectafix® device showed that this method successfully simulated the dose at the 
rectal wall interface. 
 
ii. Can EBT3 film be calibrated and used at high dose per fraction doses 
(typically 8Gy)? 
 
In this thesis film was successfully analysed and calibrated for the red channel for 
doses up to 2 Gy, and up to 14.84 Gy for the green channel, and measurements in a 
high dose setting of up to 11.95 Gy, with high dose gradients were carried out with a 
high degree of accuracy. 
   
iii. What is the accuracy and reproducibility of the EBT3 film measurements? 
 
 The data obtained was analysed by utilising a gamma analysis with suggested 
acceptance criteria of 2%/1mm with a minimum pass rate of 95%; all the 
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measurements met this criterion. The measured film data was then used to 
successfully and accurately predict dose in the high dose, high dose gradient setting 
in which it was used. 
 
Film measurement is not reproducible because each scan of the film, each scanner 
temperature, as well as the film variation inter sheet and inter batch render film are 
not a reproducible dose measurement modality. This has also been discussed by Huet 
et al. 69 
 
iv. How do the pre in-vivo EBT3 film measurements compare with radiotherapy 
treatment planning dose estimates for simple fields and for volumetric 
modulated arc (VMAT) dose delivery? 
 
Pre-in vivo measurements utilising simple fields and modulated arc beams have met 
the data extracted from TPS.  
  
VMAT delivery measurements were observed to be a good match with the TPS, as 
were the VMAT measurements which can be predicted to an accuracy of 2%/1mm 
acceptance criteria with pass rates of 98.76% and 98.23%. 
 
v. How do the in phantom EBT3 measurements compare with radiotherapy 
treatment planning dose calculations for TomoTherapy® delivery? 
 
TomoTherapy® delivery measurements have been successful in the setting they were 
analysed in when compared to the TPS, indeed they were accurate to 2%/1mm 
acceptance criteria with a pass rate of 97.26% and 100%.  
 
The method used in this thesis is a viable quality assurance method that can be used 
in-vivo during high precision prostate boost treatment, as long as a Rectafix® or 
other spacer devices are utilised. 
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9 Future Work 
 
 
For future studies the Rectafix® will need to be modified to accommodate film 
within itself so that it can be used in-vivo during patient treatment.  The proposed 
model will have the following structure: 
 
Figure 9-1 Modified Rectafix® device model 
 
The entire enclosed casing will have the same dimensions as a Rectafix® device. 
 
As seen in the study, handling the film and keeping it free from stain or damage is 
crucial for obtaining good results. The screw in the top cover that encases the film 
will keep it in a known and fixed position within the Rectafix® device.  
 
Fiducial markers are a great tool for imaging the Rectafix® within a patient pre-
treatment, and therefore should be included in the design. This is discussed further in 
Appendix A. 
 
With the Rectafix® in position, the film will be able to measure the dose received by 
the rectal wall retrospectively, and once the results are analysed ~24hrs post 
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irradiation, the dose can be measured and the plan can be modified if there is a risk 
of the rectal wall being over-irradiated due to the current plan set up.  
 
Conformal high precision boost treatments at close proximity to critical structures 
require great precision because small errors can have a huge impact, as has been 
shown in this thesis. This has the possibility of improving patient outcomes and 
increasing confidence in the plan being delivered. The collected data can also be 
used to develop a protocol and set limits according to the patient outcomes observed 
with the method employed. 
 
One drawback to this method will be an increase in department workload and it will 
take some time to complete; therefore a clinical trial is needed to justify the routine 
use of this method during prostate boost Radiotherapy. 
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APPENDIX A - FIDUCIAL IMAGES 
 
The fiducials markers were scanned using CT imaging inside the CIRS phantom to 
review the clarity of the fiducial markers and obtain a CT image of the CIRS 
phantom and Rectafix® set up to import onto the TPS and overlay patient plans, as 
required.  
 
 
Figure A-2 Coronal, lateral and sagittal view of CT image of fiducials placed on the 
anterior edge of the Rectafix® 
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Figure A-3 Coronal, lateral and sagittal view of CT image of fiducial placed on the 
side edge of the Rectafix® 
 
 As a side experiment, it was expected that future studies may involve MRI so the 
fiducial markers were also tested in MRI. A Rectafix® device with the attached 
fiducials was placed inside a cylindrical body of water to provide the required 
hydrogen molecules needed to image the Rectafix® and fiducial markers. 
 
Two scans were taken, one using the ultrashort echo-time (UTE) value of 0.07 ms 
and another in a normal sequence MRI with a TE value of 4.6 ms. UTE MRI allows 
for components to be imaged where a normal sequence MRI may show the artefacts, 
or not show them at all. 81 
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Figure A-4 Image on the left shows MRI image taken with UTE, image on right 
shows MRI image taken using normal TE. 
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Figure A-5 Coronal, lateral and sagittal view of MRI image taken using UTE. 
 
 
Figure A-6 Coronal, lateral and sagittal view of MRI image taken using normal TE. 
 
Here, the fiducials markers appear as a hole caused by an artefact in the phantom 
next to the fiducial markers, where in fact there is none because the fiducials 
themselves are not imaged. 
 
This apparent hole is much more prominent in the MR image taken with UTE, where 
it appears to be visible but with more precision, and with less artefacts and better 
quality images.  This is recommended as the modality of choice while using these 
markers.  
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